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Childhood acute leukemias are genetically complex disorders, with recurrent or 
random aberrations found in most patients. Their proper functional characterization is crucial 
for understanding the role they play in the process of leukemogenesis. We aimed to identify 
and characterize the genetic background of two leukemic entities. 
The transient myeloproliferative disorder (TMD) is a preleukemic condition that occurs 
in 10% of newborns with Down syndrome. Trisomy 21 together with in-utero gained 
mutations in the GATA1 gene are essential in TMD and represent an ideal “multi-hit” model 
to study leukemogenesis. We investigated an alternative pathogenic mechanism enabling 
TMD development in a confirmed absence of trisomy 21. Novel deletions in the GATA1 and 
JAK1 genes were described as potential drivers of this TMD. The deletion D65_C228 in GATA1 
results in the expression of an aberrant isoform, which is predicted to lose transactivation 
potential and, more importantly, to partially lose the ability of recognizing physiological DNA 
binding sites, possibly triggering TMD alone. Our thorough characterization of JAK1 F636del 
questions its role in TMD development. Analysis of JAK/STAT signaling suggested decrease of 
kinase activity upon F636 loss. Cells harboring the aberrant JAK1 did not obtain cytokine-
independent growth when assessed in the Ba/F3 assay. Moreover, JAK1 F636del had no 
impact on cell proliferation and maturation when studied in a “prenatal” environment 
represented by fetal hematopoietic stem and progenitor cells expressing mutated GATA1. 
Combined, we described the molecular events in the first case of trisomy 21-independent 
GATA1-mutated TMD. 
The ETV6-ABL1 fusion gene represents a rare recurrent event in acute lymphoblastic 
leukemia (ALL). We characterized a single chromosomal rearrangement leading to the 
formation of ETV6-ABL1 together with two novel fusion genes: ABL1-AIF1L and AIF1L-ETV6. 
The production of three in-frame fusion genes from a single rearrangement is a rare event. 
Moreover, we report, to the best of our knowledge, the first disruption of the AIF1L gene in 
leukemias. Chimeric protein analysis in HEK293T cells showed that AIF1L-ETV6 is expressed 
and localized in the nucleus, where it may bind to DNA via its ETV6 domain. We demonstrated 
the prenatal origin of the observed rearrangement by detecting the patient-specific ETV6-
ABL1 fusion gene breakpoint sequence in the patient’s Guthrie card by PCR, therefore 
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confirming that all three fusion genes are insufficient to cause overt leukemia. Additional 
“second” hit mutations were required, in this case probably represented by deletions in the 
IKZF1 and/or CDKN2A/B genes. 
Our findings regarding trisomy 21-independent TMD shed new light on the 
pathogenesis of this intensely investigated leukemia-like condition. Furthermore, our 
thorough characterization of a unique chromosomal rearrangement resulting in the prenatal 






Dětské akutní leukémie jsou geneticky komplexní poruchy hematopoézy. U většiny 
pacientů se vyskytují rekurentní či náhodné aberace, jejichž pečlivá funkční charakterizace je 
zásadní pro pochopení role, kterou hrají v procesu leukemogeneze. Naším cílem byla 
identifikace a charakterizace genetického pozadí dvou leukemických entit.  
Transientní myeloproliferativní porucha (TMD) je preleukémie, která postihuje 10% 
novorozenců s Downovým syndromem. Trisomie 21 chromozomu a in-utero získané mutace 
v genu GATA1 jsou kauzální pro vznik TMD a společně představují ideální “více-zásahový“ 
model leukemogeneze. Zaměřili jsme se na zkoumání alternativního mechanismu vzniku TMD 
bez účasti trisomie 21. U jedinečného případu TMD jsme jako potenciálně spouštěcí aberace 
popsali nové delece v genech GATA1 a JAK1. Delece D65_C228 v GATA1 způsobuje tvorbu 
poškozené izoformy, u níž se předpokládá ztráta transaktivační schopnosti a rovněž částečná 
ztráta vazby ke specifickým vazebným místům v DNA, což může stačit ke spuštění TMD. Námi 
provedená podrobná charakterizace delece F636 v JAK1 zpochybňuje význam této aberace 
pro patogenezi TMD. Analýza signalizace JAK/STAT odhalila pokles kinázové aktivity po ztrátě 
F636. Růst buněk Ba/F3, které vytvářejí poškozený JAK1, je závislý na cytokinech, podobně 
jako je tomu u buněk produkujících JAK1 divokého typu. Dále jsme prokázali, že delece F636 
v JAK1 neměla žádný dopad na růst a dozrávání buněk v “prenatálním“ prostředí, 
reprezentovaném fetálními hematopoietickými kmenovými a progenitorovými buňkami 
vytvářejícími mutovaný GATA1. V předkládané práci popisujeme molekulární děje v prvním 
známém případu TMD s mutovaným genem GATA1 a zároveň nezávislém na trisomii 21 
chromozomu. 
Fúzní gen ETV6-ABL1 je vzácný, avšak opakovaně se vyskytující genetický jev při akutní 
lymfoblastické leukémii (ALL). Popsali jsme chromosomální přestavbu vedoucí ke vzniku ETV6-
ABL1 a dvou dalších dosud nepopsaných fúzních genů ABL1-AIF1L a AIF1L-ETV6. Vznik tří 
fúzních genů, se zachovaným čtecím rámcem, z jediné přestavby je v hematologii ojedinělý 
jev. Dále zde popisujeme první známé poškození genu AIF1L u leukémií. Analýza chimérické 
bílkoviny v  buňkách HEK293T ukázala, že AIF1L-ETV6 je tvořen a umístěn v jádře, kde se 
pomocí své ETV6 domény může vázat na DNA. Pomocí metody PCR se nám v 
pacientově Guthrieho kartě podařilo prokázat specifickou zlomovou sekvence fúzního genu 
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ETV6-ABL1 a tedy prenatální původ studované chromozomální přestavby.  Díky tomu jsme 
následně potvrdili, že ETV6-ABL1 není dostatečný ke spuštění diagnostikovatelné leukémie a 
musí následovat další druhotné aberace, kterými jsou v tomto případě pravděpodobně delece 
v genech IKZF1 a/nebo CDKN2A/B.  
Naše výsledky zabývající se TMD bez trisomie 21 chromozomu přinášejí nové 
informace ohledně patogeneze tohoto intenzivně studovaného onemocnění připomínajícího 
leukémii. Podrobná charakterizace jedinečné chromozomální přestavby, která vyústila v 
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Structure of the thesis 
This thesis consists of the following sections: review of literature, aims, methods, 
results, discussion, conclusions, list of publications and presentations, list of abbreviations, 
references and the publications that I have contributed to during my Ph.D. study. Two full-text 
published first-author publications, together with one first-author manuscript under 
consideration and one co-author manuscript in revision are attached. 
 
 
Structure of the review of literature 
  The opening section of the review of literature intends to comprehensively summarize 
important knowledge regarding childhood acute leukemia. An introduction to both pediatric 
acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is presented. Emphasis 
is given to recurrent genetic alterations in pediatric AML and B-cell precursor ALL. 
 The transient myeloproliferative disorder is together with a subtype of myeloid 
leukemia present exclusively in children with Down syndrome. An introduction to these two 
entities, together with relevant information regarding the GATA and JAK genes families, which 
are involved in their development, is presented. Moreover, the role of trisomy 21 in the 




Review of literature 
1. Childhood acute leukemia 
Acute leukemia is caused by a series of events that prevent normal maturation of a 
hematopoietic precursor cell into their progeny. These mutational events on the other hand 
allow the precursors to uncontrollably proliferate, which finally results in observable clinical 
symptoms. 
Leukemia is the most common type of cancer in children and teenagers and accounts 
for 30% of all pediatric cancers (Linabery and Ross, 2008; Siegel et al., 2018; Smith et al., 2010; 
Steliarova-Foucher et al., 2017). Its treatment has become a success story of modern 
medicine. Virtually an untreatable disease in the 1950s, it is now curable in around 85% of 
cases (Siegel et al., 2018). This has been attributed to the development of chemotherapeutic 
agents, proper dosing, precise diagnostics and last but not least to correct supportive care. 
Despite of these positive developments it still remains the principal cause of death from 
cancer before 20 years of age (Smith et al., 2010). Heterogeneity presents the main challenge 
in the assessment of childhood acute leukemias. Leukemia subtypes differ not only in 
morphology and clinical presentation, but also in response to treatment and prognosis. This 
is mainly due to a broad spectrum of primary and secondary genetic aberrations (Hunger and 
Mullighan, 2015b; Iacobucci and Mullighan, 2017). Acute leukemias can be divided into two 
main subgroups by lineage origin. Acute lymphoblastic leukemia (ALL) and acute myeloid 
leukemia (AML), with ALL being five times more abundant than AML in pediatric patients 
(Hunger and Mullighan, 2015a). The incidence of acute leukemias gradually switches during 
aging, with AML taking lead and finally dominating in older adults (Fig. 1) (Dores et al., 2012; 
Hein et al., 2020). 
The etiology of leukemias remains largely unknown. The generally accepted theory 
suggests that leukemias originate from a combination of exposition to various risk factors, 
genetic predisposition and chance. A minority of cases have been linked to chemicals like for 
example benzene (Savitz and Andrews, 1997) and to exposure to radiation (Greaves, 2006; 
Preston et al., 1994). The main genetic factor associated with increased risk of leukemia is 
Down syndrome, followed by rare entities generally predisposing to various types of cancer, 
namely Ataxia telangiectasia, Fanconi anemia and Li Fraumeni (Stieglitz and Loh, 2013). 
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Moreover germline variants are believed to be involved in the etiology of about 5% of 
childhood leukemias (Zhang et al., 2015).  
 
Figure 2: Age-specific incidence rates of AML and ALL (adapted from Hein et al., 2020) 
 
1.1. Genetic aberrations in leukemia 
Sequential accumulation of both genetic and epigenetic aberrations represent the 
main hallmark of cancer. These alterations can be either inherited (germline, constitutional) 
or acquired (somatic). During the process of leukemogenic transformation, cells may acquire 
a wide spectrum of mutations, including small insertions and deletions (indels), single 
nucleotide substitutions (point mutations), as well as a wide array of structural variations, like 
for example chromosomal translocations (Fig. 2) or more complex rearrangements. These 
changes of the genetic material of a cancer cell lead to gene expression profile alterations, 
subsequently affecting cell differentiation, growth and regulation of apoptosis (Bailey et al., 
2018; Dawson and Kouzarides, 2012; Mitelman et al., 2007; Stratton et al., 2009). The advent 
of next generation sequencing technologies has allowed detailed investigation of these 
genetic events. 
The main subtypes of both AML and ALL involve a broad spectrum of genetic 
alterations, including deletions and point mutations, however, they are mainly characterized 
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by chromosomal changes such as translocations or hyperdiploidy (Look, 1997; Raimondi et al., 
1999). Chromosomal translocations (Fig. 2) involve gene recombination or juxtaposition, 
which can result in dysregulation of oncogene expression by an association with a 
constitutively active regulatory element, like for example MYC with the T-cell receptor (TCR) 
or immunoglobulin heavy chain (IGH) enhancer (Rabbitts, 1994). However, in leukemia, 
usually an in-frame fusion or chimeric gene is created, resulting in the production of a hybrid 
protein. This altered protein frequently results in aberrant kinase activity or transcriptional 
regulation (Look, 1997; Rowley, 1998). A striking feature of leukemic chromosomal 
translocations is their association with biologically distinct leukemic subtypes. In general, 
chromosomal translocations in leukemia tend to be balanced or reciprocal and stable. These 
chromosomal changes usually reflect a stable early occurring single “hit” (Rabbitts, 1994). This 
distinguishes them from other pediatric malignancies, like for example epithelial carcinomas, 
commonly harboring unbalanced translocations and numerous deletions (Lengauer, 2001). 
The principal types of structural chromosomal aberrations are shown in Figure 2. 
For a given chromosomal translocation, the genomic regions in which recombination 
occurs are either clustered or specific and localized. When clustered, they are known as 
breakpoint cluster regions (BCR) which occur in introns and vary in size, therefore each patient 
harbors a unique breakpoint in the DNA of a particular leukemic clone (Reiter et al., 2003; Xiao 
et al., 2001). In lymphoid cancers DNA breaks may occur by aberrant processing of DNA by 
RAG (recombination activating gene) proteins which coordinate V(D)J recombination (Kuppers 
and Dalla-Favera, 2001). V(D)J recombination is frequently involved in translocations found in 
pediatric T-cell precursor ALL, which repeatedly involve the TCR loci (Brown et al., 1990). The 
more abundant B-cell precursor ALL (BCP-ALL) however only rarely involves V(D)J 
recombination. In this case, the more common chromosomal translocations harbor dispersed 
breakpoints, similarly to those found in myeloid leukemias (Reichel et al., 1998; Reiter et al., 
2003; van der Reijden et al., 1999; Wiemels et al., 2000; Xiao et al., 2001). Another mechanism 
involved in translocation and DNA breakpoint formation has been linked with the dysfunction 
of topoisomerase II, which plays a crucial role during DNA replication (Felix, 1998; Pedersen-
Bjergaard and Rowley, 1994; Rowley and Olney, 2002). Treatment-related leukemias have 
been associated with topoisomerase II dysfunction due to the use of topoisomerase II–
targeting drugs (Cowell and Austin, 2012; Felix et al., 2006; Rowley and Olney, 2002).  
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Interestingly, similar chromosomal translocations as found in therapy-related leukemias are 
commonly seen in de novo infant acute leukemias, like for example those resulting in KMT2A 
fusions (De Braekeleer et al., 2005; Eguchi et al., 2003; Felix and Lange, 1999; Slater et al., 
2002). The possibility of a prenatal origin of a leukemia associated chromosomal translocation 
originating already in utero was first indirectly suggested by a case of monozygotic twins 
harboring an identical leukemia genotype (Clarkson and Boyse, 1971; Greaves et al., 2003). 
International studies of concordant twin leukemia cases helped to investigate this hypothesis 
by studying genomic breakpoints of translocations for KMT2A fusions (Ford et al., 1993; Gill 
Super et al., 1994; Megonigal et al., 1998). Moreover, archived neonatal blood spots, also 
known as Guthrie cards, invented by Robert Guthrie in 1963 in order to screen newborns for 
phenylketonuria, provided valuable material to study non-twinned leukemia patients (Guthrie 
and Susi, 1963; Wiemels et al., 1999). Gale and colleagues gave the first evidence of the 
presence of leukemia fusion genes in archived neonatal blood spots (Gale et al., 1997). 
Subsequently prenatal origin was shown for the ETV6-RUNX1 translocation (Hjalgrim et al., 
2002; McHale et al., 2003; Wiemels et al., 1999). Not only fusion genes, but also point 
mutations specific for leukemias were detected in Guthrie cards. Importantly, mutations in 
the GATA1 gene in Down syndrome acute megakaryoblastic leukemia (DS-AMKL), in transient 
myeloproliferative disease (TMD) patients (Ahmed et al., 2004) and in the NOTCH1 gene 
present in T-ALL patients (Eguchi-Ishimae et al., 2008). The backtracking studies revealed that 
preleukemic cells harboring early genetic aberrations can persist in the patient’s bone marrow 
for years before acquiring additional necessary hits for leukemic transformation. Most 
pediatric leukemias therefore very probably originate prenatally through various 
chromosomal translocations (Bateman et al., 2010; Cazzaniga et al., 2011; Greaves, 1999; 
Greaves et al., 2003; Hong et al., 2008; Maia et al., 2004; Wiemels et al., 1999). Importantly, 
various studies indicate that a single chromosomal translocation, representing the so-called 
“first hit” which initiates a preleukemic state where the hematopoietic precursor is provided 
with possible proliferative or function advantage, is usually insufficient to cause overt 
leukemia and additional genetic alterations are required (Fig. 3) (Gonzalez-Herrero et al., 
2018; Higuchi et al., 2002; Hong et al., 2008; Ma et al., 2013; Yuan et al., 2001). Twin studies 
confirmed that these additional alterations, including single nucleotide variants (SNV) and 
copy number aberrations (CAN), most likely occur postnatally (Bateman et al., 2010; Cazzaniga 
et al., 2011). Similarly, the vast majority of ongoing V(D)J rearrangements occurring in IGH are 
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subclonal and differ in twin pairs (Alpar et al., 2015). Common cooperating oncogenic lesions, 
which reprogram the cell into an autonomously proliferating blast with blocked differentiation 
and clonal expansion potential, are in ALL represented by alterations in the CDKN2A, CDKN2B, 
PAX5, RAG1, RAG2, IKZF1 genes (Iacobucci and Mullighan, 2017; Mullighan et al., 2007) and in 
AML by alterations in the JAK2, FLT3, KIT, NRAS, KRAS, DNMT3A genes (Beghini et al., 2000; 
Krauth et al., 2014; Schnittger et al., 2002; Shin et al., 2016). 
 
Figure 2: Principal types of structural chromosomal aberrations.  
 
 
Figure 3: Multi-step model of leukemogenesis. Genetic alterations leading to B lymphoblastic 




1.2. Acute myeloid leukemia 
Acute myeloid leukemia accounts for 15-20% of childhood leukemias. The highest 
incidence of AML in pediatric patients is within the first year of life (Fig. 1) (Dores et al., 2012). 
Although major improvements in the survival rates for pediatric AML patients have been 
achieved in the past decade, with a 5-year overall survival of around 70% (Creutzig et al., 
2012), they are still considerably lower than for children with ALL (Siegel et al., 2018; Ward et 
al., 2014).  
AML is a very heterogeneous disease, both from a clinical, molecular and 
pathophysiological view point. Various myeloid hematopoietic progenitors, encompassing the 
erythroid, granulocyte, monocyte and megakaryocyte lineages can be affected giving rise to a 
myriad of presentations. Originally myeloid malignancies have been divided and characterized 
by the French-American-Berlin (FAB) classification mainly by morphology and 
immunophenotyping (Bennett et al., 1976). However, with gradual emergence of genetic 
approaches, which enabled a more complex characterization of the blast population on 
molecular level, and their incorporation into routine diagnostics required a revision of the 
classification, which was introduced by the World Health Organization (WHO) in 2002 
(Vardiman et al., 2002) and was then revised in 2008 (Tefferi and Vardiman, 2008; Vardiman 
et al., 2009). Mainly, due to numerous advances associated with next-generation sequencing 
methods and gene expression analysis, an even more precise classification of AML and related 
neoplasms was presented in 2016 (Arber et al., 2016). 
Leukemic blast infiltration into numerous tissues and organs results in a plethora of 
clinical symptoms in AML. The alteration of bone marrow microenvironment leads to anemia, 
thrombocytopenia and neutropenia. Extramedullary lesions include the spleen (resulting in 
hepatosplenomegaly), skin, lymph nodes and the central nervous system (CNS).  
Morphology, immunophenotyping, fluorescent in-situ hybridization (FISH), 
karyotyping and molecular genetic analysis of the bone marrow, eventually of the peripheral 
blood, are the basic diagnostic requirements in pediatric AML. Moreover, CNS involvement is 
investigated at diagnosis by examining the cerebrospinal fluid (Creutzig et al., 2012). 
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Assessing proper treatment intensity in AML patients follows risk stratification, which 
is based on the underlying leukemia biology, molecular genetics and response to therapy. 
Intensive induction therapy is initiated shortly after diagnosis of AML.  
1.2.1. Genetic aberrations in AML 
A number of aberrantly expressed genes and gene mutations have been described in 
childhood AML (Fig. 4). These genetic events are generally divided into two classes (Renneville 
et al., 2008). Type I class includes mutations that present the progenitor cell with a 
proliferative advantage without fully transforming it into a leukemic cell, like for example 
mutation in the JAK2, FLT3, KIT, CBL genes and mutations in the RAS-RAF-ERK signal 
transduction pathway, NRAS, KRAS and PTPN11 (Zuna and Zaliova, 2015). On the other hand 
genetic mutations of the type II class mostly affect the differentiation potential and 
subsequently apoptosis of the leukemic cell. Fusion genes, like for example PML-RARA, 
RUNX1-RUNX1T1 and CBFB-MYH11, that result from chromosomal translocations, are the 
main representatives of the second class aberrations (Dash and Gilliland, 2001; Kelly and 
Gilliland, 2002; Renneville et al., 2008). With respect to the two-hit theory, AML results from 
a cooperation of at least two mutations from the above described classes (Kelly and Gilliland, 
2002). The acquisition of genetic aberration in AML occurs in a stepwise manner. Both the 
order and the type of the acquired mutations affects the hematopoietic stem cell (HSC). It 
makes it either more likely or less likely to evolve into full-blown leukemia (Grove and 
Vassiliou, 2014). 
Alterations that are associated with a favourable prognosis in pediatric AML include 
the fusion genes RUNX1-RUNX1T1, CBFB-MYH11, PML-RARA and mutations in genes NPM1 
and CEBPA (Harrison et al., 2010; Rubnitz and Inaba, 2012; Rubnitz et al., 2010; von Neuhoff 
et al., 2010). 
Monosomy 7, monosomy 5 and del(5q) have been associated with poor prognosis  
(Hasle et al., 2007). Fortunately, these chromosomal abnormalities present only 2-4% of AML 
cases. On the other hand, activating mutations in the form of internal tandem duplications of 
the FLT3 gene (FLT3/ITD mutations) represent approximately 10% of AML cases and are 
associated with poor prognosis when exhibiting a high ratio of mutant to normal alleles (Levis 
and Small, 2003; Meshinchi et al., 2006; Staffas et al., 2011).  
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The most common recurrent karyotypic abnormalities in pediatric AML are discussed 
below. The list is not exhaustive. 
KMT2A-rearranged AML 
KMT2A gene (previously known as the MLL gene) fusions resulting from chromosome 
11q23 rearrangements are common in pediatric AML, comprising 10 to 20% of cases overall. 
They are especially prevalent in infants (Balgobind et al., 2009; Creutzig et al., 2012; Forestier 
et al., 2003; Masetti et al., 2015). The KMT2A gene is fused to more than 20 gene partners, 
however the MLLT3 gene (AF9 gene) located on chromosome 22 is the most common 
translocation partner (Meyer et al., 2006; Shih et al., 2006). Acute myeloid leukemia with the 
KMT2A-MLLT3 fusion gene is considered as a distinct subtype of AML by the WHO 
classification and is associated with an intermediate prognosis. However, other translocation 
partners of KMT2A in children demonstrated a wide variability in survival (Coenen et al., 2011). 
t(8;21)/RUNX1-RUNX1T1 AML 
The t(8;21)(q22;q22) chromosomal translocation is found in 8-13% of pediatric AML 
cases and results in the production of the fusion gene RUNX1-RUNX1T1 (Forestier et al., 2003; 
Rubnitz et al., 2002). Secondary cooperating mutations in NRAS, KRAS or KIT are frequently 
present in AML patients harboring this particular translocation (Goemans et al., 2005; Krauth 
et al., 2014). Interestingly the RUNX1-RUNX1T1 fusion gene was one of the first to be used for 
the monitoring of minimal residual disease (MRD) (Yin et al., 2012). The RUNX1-RUNX1T1 
chimeric protein causes a disruption of the normal function of the transcription factor complex 
CBF which regulates normal hematopoiesis (Downing, 1999; Licht, 2001).  
inv(16)/t(16;16)/CBFB-MYH11 AML 
The inversion inv(16)(p13.1;q22) or translocation t(16;16)(p13.1;q22) of chromosome 
16 is present in 5-10% of childhood AML cases (Creutzig et al., 2012). Both of these cytogenetic 
abnormalities give rise to a fusion of the CBFB gene with the MYH11 gene on chromosome 16 
(Sinha et al., 2015; Speck and Gilliland, 2002). The CBFB-MYH11 chimeric fusion protein 
deregulates transcriptional activity effecting cell differentiation, regulation of apoptosis and 
proliferation, similarly to RUNX1-RUNX1T1 (Shigesada et al., 2004; Steffen et al., 2005). This 
subtype of pediatric AML usually presents with a myelomonocytic morphology. Frequent 
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eosinophils are present in the bone marrow and have characteristic abnormal immature 
basophilic granules (Larson et al., 1986). 
t(15;17)/PML-RARA AML 
The PML-RARA fusion gene results from the translocation t(15;17)(q22;q12) and is 
associated with acute promyelocytic leukemia (APL) in which it represents the most common 
genetic aberration (Warrell, 1993). The fusion gene is present in 6-10% of all pediatric AML 
patients (Creutzig et al., 2012). The RARA gene encodes the retinoic acid receptor alfa protein 
which serves as a nuclear receptor. It is fused to the PML gene, which encodes for a myeloid 
transcription factor. The chimeric fusion protein results in a permanent repression of genomic 
expression finally leading to dysregulation of cell differentiation, self-renewal and apoptosis 
(Steffen et al., 2005). The repressive function of PML-RARA can be inhibited by high doses of 
the all-trans retinoid acid (ATRA), representing the first successful targeted molecular therapy 
applied in the treatment of leukemia which changed the prognosis of APL from dismal to 
excellent (Huang et al., 1988; Wang and Chen, 2008). 
1.2.2. Minimal residual disease monitoring in AML 
 The persistence of leukemic cells after therapy at levels undetectable by morphology 
is termed minimal residual disease (MRD). Its assessment in routine clinical practice has 
become indispensable in both pediatric and adult ALL (Pui et al., 2017; van Dongen et al., 
2015). On the other hand, its applicability in pediatric AML still remains largely problematic. 
Several platforms are currently available for MRD monitoring in AML, including 
multiparametric flow cytometry (MFC), real-time quantitative polymerase chain reaction (RT-
qPCR) and next-generation sequencing (NGS), each suitable for distinct leukemia subtypes 
(Schuurhuis et al., 2018; Voso et al., 2019). RT-qPCR assesses MRD by amplifying genetic 
abnormalities associated with leukemia, mainly RNA transcripts of fusion genes. The currently 
validated molecular targets for MRD monitoring by RT-qPCR, in which it plays a superior role 
over MFC, include the PML-RARA translocation, the core-binding factor (CBF) translocations 
RUNX1-RUNX1T1 and CBFB-MYH11, and mutations in the NPM1 gene (Gabert et al., 2003; 




Figure 4: Recurrent cytogenetic aberrations in childhood AML, t (translocation), inv (inversion) 
(adapted from Creutzig et al., 2012) 
 
1.3. Acute lymphoblastic leukemia 
Treatment of pediatric ALL has advanced tremendously in the last few decades, with 
current event free survival rate of approximately 90% (Hunger et al., 2012). Nevertheless cure 
rates range from as low as 20% to as high as 95% depending on the ALL subgroup. ALL accounts 
for 25% of all childhood cancers, making it the most common pediatric malignancy, with a 
peak incidence between 2 to 5 years, being more prevalent in boys (Fig. 1) (Hunger and 
Mullighan, 2015a; Pui et al., 2004). A number of genetic factors were linked with an increased 
risk of pediatric ALL, most notably DS (Buitenkamp et al., 2014). Moreover, several 
polymorphic variants identified by genome-wide association studies, including IKZF1, GATA3, 
ARID5B, CDKN2A and CEBPE, were associated with increased ALL risk (Papaemmanuil et al., 
2009; Sherborne et al., 2010; Trevino et al., 2009). 
Clinical presentation usually reflects the extent of bone marrow infiltration with 
leukemic blasts and extramedullary involvement. Typical symptoms include 
spleno/hepatosplenomegaly, lymphadenopathy, fever and signs of bleeding. Laboratory 
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findings usually demonstrate anemia, neutropenia and thrombocytopenia, reflecting a 
disorder of hematopoiesis. The presence of leukemia in the CNS usually results from the 
spread of leukemic cells. Fortunately, it is found in only 5% of B-ALL patients at the time of 
diagnosis (Laningham et al., 2007). 
A bone marrow aspirate is ordinarily necessary for establishing definite diagnosis of 
leukemia, by identifying the morphology of lymphoblasts via microscopical analysis together 
with defining cell lineage and developmental stage by flow cytometry (Pui et al., 2008). 
Proper risk stratification of ALL patients has immensely improved the therapy of this 
disease. Risk of relapse is the main factor driving therapy intensity. Treatment usually lasts for 
approximately 2 to 3 years. The first phase of treatment, the induction phase, is initiated right 
after diagnosis and is meant to achieve disease remission and the re-establishment of normal 
hematopoiesis in the bone marrow. Consolidation phase, together with intensification play a 
major role in the eradication of persisting leukemic cells that are below the morphological 
detection levels and in the achievement of long lasting remission.  
The majority (80-85%) of pediatric ALL cases are represented by BCP-ALL. These cases 
originated from an early B-cell progenitor. Approximately 15% of pediatric ALL, originated 
from an early T-cell progenitor and therefore represent T-lymphoblastic leukemia (T-ALL).  
1.3.1 Genetic aberrations in ALL 
Pediatric ALL comprises of multiple subtypes with various chromosomal 
rearrangements, gains/deletions of DNA and mutations of common cellular pathways (Fig. 5). 
Precise identification of these genetic alterations is important for diagnosis, prognostic risk 
stratification and subsequent adjustments of therapy. The detection of genetic abnormalities 
is done by conventional genetic methods like fluorescence in-situ hybridization (FISH), 
karyotyping and polymerase chain reaction (PCR) together with the measurement of DNA 
ploidy by flow cytometry (Pui et al., 2004).  
The introduction of genome-wide approaches, namely whole-genome sequencing, 
whole-exome sequencing (WES), whole-transcriptome sequencing (RNA-seq), single 
nucleotide polymorphism arrays (SNP array) together with genome wide gene expression 
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profiling has enabled us to distinguish novel subtypes of ALL (Gu et al., 2019; Iacobucci and 
Mullighan, 2017; Lilljebjorn and Fioretos, 2017). 
 
 
Figure 5: Prevalence of the most common genetic aberrations in pediatric ALL (adapted from 




Selected BCP-ALL subtypes are introduced below. The list is not exhaustive and doesn’t include 
all known and described BCP-ALL subtypes.  
High hyperdiploid ALL 
Leukemic blasts harboring 51-67 chromosomes are defined as high hyperdiploid. This 
most common cytogenetic abnormality in pediatric BCP-ALL is associated with a favorable 
prognosis. The higher the chromosome number, the better the prognosis (Dastugue et al., 
2013). The gain of chromosomes in high hyperdiploid ALL is nonrandom and is featured by 
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chromosomes 21, X, 6, 4, 10, 17, 14 and 18 (Paulsson et al., 2010; Paulsson and Johansson, 
2009). High hyperdiploidy is considered an early event in leukemogenesis as was confirmed 
by backtracking studies (Gruhn et al., 2008; Taub et al., 2002). It has been suggested that the 
gain of extra chromosomes occurs simultaneously in a single cell division (Paulsson and 
Johansson, 2009). 
Hypodiploid ALL 
Hypodiploid ALL with less than 44 chromosomes has an extremely poor outcome. 
Patients with hypodiploid blast cells are further stratified by chromosome number into three 
subgroups. The near haploid group (24-31) has an event free survival (EFS) as low as 30%. 
Slightly better are the EFS for the two remaining subgroups, low hypodiploid (32-39) and high 
hypodiploid (40-43) (Holmfeldt et al., 2013; Nachman et al., 2007). 
 t(12;21)/ETV6-RUNX1 ALL 
 The most common chromosomal translocation in pediatric BCP-ALL, 
t(12;21)(p13;q22), results in the production of the fusion gene ETV6-RUNX1 (TEL-AML1) 
(Romana et al., 1995b). It is very common in pediatric patients and almost absent in adults. It 
has been shown that this aberration frequently originates in utero (Wiemels et al., 1999). 
Usually cryptic, the translocation is detectable only by FISH analysis and not by conventional 
karyotyping. The oncogenic fusion protein promotes self-renewal and differentiation of B-
progenitor cells. It seems to be necessary in leukemogenesis, but is alone insufficient to cause 
overt leukemia (Morrow et al., 2004). Patients with this ALL subtype have a very favorable 
prognosis. Occasionally relapses do occur, but tend to respond well to chemotherapy 
(Bhojwani et al., 2012; Loh et al., 2006; Zuna et al., 1999).  
KMT2A-rearranged ALL 
 Rearrangements of the KMT2A gene occur in both ALL and AML. They are specifically 
related to infant leukemia in patients younger than 1 year (Muntean and Hess, 2012; Slany, 
2009). Nearly all KMT2A abnormalities are KMT2A N-terminus in-frame fusions with fusion 
partners, which create a novel oncogene. The KMT2A gene is considered quite promiscuous, 
with more than 120 gene fusion partners described (Meyer et al., 2013; Meyer et al., 2009). 
Nevertheless, nine partner genes represent almost 90% of all rearrangements (Meyer et al., 
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2013; Muntean and Hess, 2012). KMT2A most commonly fuses with AFF1 (AF4), MLLT1 (ENL) 
and MLLT3 (AF9). Evidence points to the in utero origin of KMT2A-rearranged leukemias. 
Moreover, they harbor fewer cooperating mutations, when compared with other B-ALL 
leukemias, indicating the strength of the KMT2A oncogene. Patients with the KMT2A-
rearrangement have a significantly poorer prognosis and are treated with intensified therapy 
in most protocols (Meyer et al., 2013; Meyer et al., 2009). 
t(9;22)/BCR-ABL1 ALL 
The BCR-ABL1 fusion oncogene, located on the Philadelphia (Ph) chromosome, results 
from a balanced translocation of chromosome 9 and 22. It was the first cytogenetic 
abnormality to be associated with a particular malignity (Nowell and Hungerford, 1960; 
Rowley, 1973). A portion of the ABL1 tyrosine kinase, residing on chromosome 9, is fused with 
the BCR gene on chromosome 22. The resulting BCR-ABL1 fusion gene generates a 
constitutively active tyrosine kinase, which subsequently deregulates and aberrantly activates 
a number of crucial signal transduction pathways (Lugo et al., 1990). The fusion gene is a 
typical feature of adult chronic myeloid leukemia (CML) and also ALL. It is less common in 
pediatric ALL were it is presents in about 3% of cases. There are two main forms of the fusion 
gene depending on the BCR break point. The Major BCR-ABL1 variant, resulting from 
breakpoints in the major breakpoint cluster region, is typically present in CML patients and 
gives rises to the 210kD protein p210. In ALL patients we tend to find the minor BCR-ABL1 
fusion gene variant which results in the production of protein p190 (Melo, 1996). Until 
recently, the BCR-ABL1 fusion gene was associated with an inferior prognosis (Arico et al., 
2000). The introduction of a specific tyrosine kinase inhibitor, imatinib mesylate, which is 
active against the fusion protein has significantly improved survival (Biondi et al., 2012; Druker 
et al., 2001; Jeha et al., 2014; Schultz et al., 2009). 
B-other ALL 
An important subgroup of precursor B-ALL leukemias are the so-called “B-others”, 
which are represented by leukemias without the above described genetic aberrations and 
account for approximately 25% of all B-ALL cases (Fig. 5) (Inaba et al., 2013; Zaliova et al., 
2019). The availability of modern genome-wide approaches enabled investigation of the 
genetic background of B-other leukemias. A number of novel subtypes have been described 
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within B-other ALL based on unique gene expression signature profiles and recurrent genetic 
aberrations (Gu et al., 2019; Hirabayashi et al., 2017; Lilljebjorn et al., 2016; Rand et al., 2011; 
Zaliova et al., 2019).   
In addition to the subtype defining aberrations, additional genetic abnormalities have 
been identified, with some proven to be therapeutically relevant, like for example the IKZF1 
deletion (IKZF1del) which has been associated with increased risk of relapse (Clappier et al., 
2015; Dorge et al., 2013; Mullighan et al., 2009b). Moreover a group of aberrations in genes 
encoding cytokine receptors, kinases and regulators of intracellular signaling which eventually 
result in the activation of kinases seems to be therapeutically relevant, namely aberrations in 
the CRLF2, KRAS, NRAS, ZEB2 and fusions involving JAK2, ABL1, EPOR (Mullighan et al., 2009a; 
Perentesis et al., 2004; Roberts et al., 2012; Zhang et al., 2011).  
BCR-ABL1-like/Ph-like ALL  
The BCR-ABL1-like ALL is a new entity, which was recognized by the 2016 WHO 
classification, mainly due to its responsiveness to tyrosine kinase inhibitors (TKI) and clinical 
relevance (Arber et al., 2016). This subgroup lacks the BCR-ABL1 fusion gene, but its expression 
profile resembles BCR-ABL1-positive ALLs (Den Boer et al., 2009; Mullighan et al., 2009b). The 
incidence of BCR-ABL1-like ALL increases with age (Roberts et al., 2017; Roberts et al., 2014a). 
It is associated with poor response to therapy and overall poor prognosis (Roberts et al., 
2014a). Recurrent genetic aberrations in BCR-ABL1-like ALLs are represented by IKZF1 
deletions, mutations and rearrangements of the CRLF2 gene, rearrangement of JAK2 and ABL-
class genes and mutations activating the RAS and JAK/STAT signaling pathways (Roberts et al., 
2017; Roberts et al., 2014a).  
In BCR-ABL1-like ALLs CRLF2 is either translocated into the heavy chain locus of the 
immunoglobulin gene (IGH) or a deletion upstream of the CRLF2 gene causes the production 
of a P2RY8-CRLF2 fusion (Yoda et al., 2010). CRLF2-rearranged ALLs usually harbor additional 
aberrations activating signaling pathways (Mullighan et al., 2009c; Roberts et al., 2017). Poor 
prognosis has led to the investigation of specific kinase inhibitors which would target the 





The ETV6-RUNX1-like leukemias display the same gene expression pattern as ETV6-
RUNX1-positive ALL cases, albeit not having the fusion gene (Lilljebjorn et al., 2016; Zaliova et 
al., 2017). This subgroup harbors deletions or various structural aberrations of the ETV6 gene 
together with alterations of IKZF1. The expression of surface markers CD27 and CD44 is also 
similar as in ETV6-RUNX1-positive ALL cases (Zaliova et al., 2017), supporting the biological 
proximity of these two ALL subgroups. 
DUX4-rearranged ALL 
The deregulation of the transcription factor DUX4 (double homeobox 4 gene) in 
childhood ALL has been linked with a distinct gene expression profile and immunophenotype 
(Lilljebjorn et al., 2016; Liu et al., 2016; Yasuda et al., 2016; Zhang et al., 2016). DUX4 is located 
on chromosome 4, in the subtelomeric D4Z4 repeat region. The translocation of DUX4 to IGH 
causes the expression of its truncated isoform in B lymphocytes (Lilljebjorn et al., 2016; Liu et 
al., 2016; Yasuda et al., 2016; Zhang et al., 2016). Rarely, DUX4 can be inserted into the ERG 
gene (Lilljebjorn et al., 2016). The short DUX4 protein binds to the intragenic region of the 
gene encoding ERG and leads to the expression of an aberrant ERG protein, which inhibits ERG 
wild type transcriptional activity (Zhang et al., 2016).  
ZNF384-rearranged ALL 
The zinc finger encoding gene ZNF384 plays an important role in the process of matrix 
metalloprotease regulation. The rearrangements of ZNF384 involves a fusion partner gene, 
usually a chromatin modifier or transcriptional regulator (for example: CREBBP, EP300, TAF15, 
ARID1B, TCF3) (Hirabayashi et al., 2017; Liu et al., 2016; Shago et al., 2016; Yasuda et al., 2016). 
The B precursor leukemias harboring the ZNF384 rearrangement have intermediate 
prognosis.  
MEF2D-rearranged ALL 
Rearrangements of the myocyte enhancer factor 2D (MEF2D) are present in 
approximately 3% of children with BCP-ALL and 6% of adults (Liu et al., 2016; Zaliova et al., 
2019). MEF2D is most commonly rearranged to BCL9 (Gu et al., 2016). The resulting fusion 
proteins are more active and show transforming potential. Increased transcriptional activity 
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in the leukemic cells leads to enhanced expression of HDAC9 (histone deacetylase 9), making 
them particularly sensitive to histone deacetylase inhibitors in vivo (Gu et al., 2016). 
1.3.1.2. ETV6-ABL1-positive ALL 
The ETV6-ABL1 fusion is a rare event in ALL were it represent 0,2% of cases in children 
and 0,4% of cases in adults. Moreover it is also recurrently found in patients with CML without 
BCR-ABL1 and in AML (Zaliova et al., 2016; Zuna et al., 2010). Similarly to the BCR-ABL1 fusion 
gene, which is far more frequent, it is a kinase activating lesion leading to the deregulation of 
cellular survival and growth and subsequently transforming the affected cell into a leukemic 
blast (Hannemann et al., 1998; Million et al., 2004; Okuda et al., 1996; Papadopoulos et al., 
1995; Pendergast et al., 1993). Interestingly ETV6-ABL1 does not induce leukemic 
transformation in mice, unlike BCR-ABL1. On the other hand, it causes a chronic 
myeloproliferation, that is similar to the one induced by BCR-ABL1 in CML (Million et al., 2002). 
Its genomic profile closely resembles the BCR-ABL1-positive and BCR-ABL1-like ALLs. Most 
patients harbor deletions in the CDKN2A/B and IKZF1 genes (Zaliova et al., 2019). The 
expression profile analysis clusters patients positive for ETV6-ABL1 parallel to the BCR-ABL1 
cases, therefore usually classifying them into the BCR-ABL1-like ALL subgroup. The ETV6-ABL1 
fusion gene is associated with poor prognosis in acute leukemias (Zuna et al., 2010). It has 
been shown in vitro that the aberrant kinase can be inhibited by imatinib, a TKI used for 
treatment of BCR-ABL1-positive leukemias, therefore making it a potential treatment option 
also in leukemias harboring the ETV6-ABL1 fusion (Carroll et al., 1997; Zaliova et al., 2016).  
1.3.1.3. T-ALL 
More than half of T-ALL patients harbor chromosomal translocations. These 
translocations usually involve the T-cell receptor alfa (TRA), T-cell receptor delta (TRD) loci 
(14q11) and the T-cell receptor beta (TRB) region (7q34). The chromosomal rearrangements 
juxtapose the T-cell receptor genes to genes encoding for transcription factors, such as LYL1, 
TAL1, TAL2, LMO1, LMO2, TLX1, TLX3, MYC, MYB and HOXA genes. Moreover, T-ALLs can 
contain cryptic rearrangements of ABL1, like ETV6-ABL1, EML1-ABL1 and NUP214-ABL1 
(Durinck et al., 2015; Liu et al., 2017). 
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Activating mutations in NOTCH1 are present in approximately 60% of T-ALLs (Weng et 
al., 2004). They are together with CDKN2A and CDKN2B deletions the most prevalent T-ALL 
alterations (Girardi et al., 2017). Other molecular alterations include JAK1 and JAK3 mutations 
resulting in constitutive activation of JAK/STAT signaling (Liu et al., 2017; Van Vlierberghe and 
Ferrando, 2012). 
2. Myeloid leukemogenesis in Down syndrome 
Down syndrome (DS) was described clinically in 1866 by Langdon Down (Down, 1866) 
and was associated with trisomy of the 21 chromosome a century later (Lejeune et al., 1959). 
Prevalence of the disorder correlates with maternal age and is approximately 1/700 (Mai et 
al., 2019). In 95% of cases, trisomy 21 in Down syndrome patients is due to chromosomal non-
disjunction in meiosis. Three percent of patients harbor translocations that involve the 
additional 21 chromosome or its part. A small group of patients, approximately 2%, are 
affected by mosaic Down syndrome, where a portion of the patient’s cells have trisomy 21, 
while the rest are disomic. The range of the affected cells may vary significantly and can be 
organ or tissue specific. The clinical presentation of DS is associated with typical facial features 
(almond shaped eyes, flattened face, macroglossia, short neck), weak muscle tone, 
developmental delay, congenital heart disease, Alzheimer’s and importantly leukemia (Roizen 
and Patterson, 2003). Interestingly, DS is associated with a lower incidence of solid tumours 
(Hasle et al., 2000). 
A broad spectrum of hematological malignancies has been described in patients with 
DS, ranging from benign to malignant conditions (David et al., 1996; de Hingh et al., 2005; 
Henry et al., 2007; Kivivuori et al., 1996; Starc, 1992; Watts et al., 1999; Webb et al., 2007). 
The incidence of both AML and ALL is increased in DS patients (Table 1) (Hasle et al., 2000). 
Acute myeloid leukemia in DS occurs at a younger age.  The most striking difference from the 
general population is the risk of acute megakaryoblastic leukemia (AMKL), which is 500 times 
higher in patients with DS, than in healthy age-matched individuals. AMKL is a subtype of AML 
and it may be preceded, in DS patients, by a preleukemic phase termed transient 
myeloproliferative disorder (TMD). 
Children with DS are more sensitive to chemotherapy and therefore intensity reduced 
regiments in the treatment of AML are recommended, usually without the need of 
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hematopoietic stem cell transplantation (HSCT) (Creutzig et al., 2012). This approach results 
in survival rates of more than 85% (Creutzig et al., 2005; Kudo et al., 2010; Kudo et al., 2007). 
On the other hand, survival rates of children with ALL in DS are poorer than in non-DS ALL 
patients, mainly due to higher relapse occurrence (Buitenkamp et al., 2014).  
 
Table 1: Acute leukemia in children with and without Down syndrome (adapted from Hitzler 
and Zipursky, 2005).  
 
Trisomy 21 is believed to play an essential role in the pathogenesis of TMD and DS-
AMKL. This is exemplified by the fact that both TMD and DS-AMKL require trisomy 21 in the 
blast cells.  
Despite, that the long arm of chromosome 21 (HSA21) is the most studied 
chromosome (Antonarakis, 2017) its biological role in leukemogenesis remains elusive. 
Trisomy 21 has been shown to increase fetal hematopoietic stem cell self-renewal. It 
accelerates the expansion of early hematopoietic progenitor cells, namely the erythro-
megakaryocytic progenitor compartment (Chou et al., 2008). Moreover, it has been 
postulated by Banno and colleagues, that gene dosage alterations of ERG, RUNX1 and ETS2, 
which are located in a 4-Mb region on HSA21, is critical for the deregulating effects on 
hematopoiesis (Banno et al., 2016). 
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To study the contribution of trisomy 21, induced pluripotent stem (iPS) cells originating 
from DS patients have been established and analyzed for hematopoietic differentiation (Chou 
et al., 2012; Li et al., 2012; Maclean et al., 2012). When cultured under conditions supporting 
primitive hematopoiesis, erythropoiesis was enhanced, myelopoiesis was reduced and 
megakaryocytes were normally produced (Chou et al., 2012). Interestingly, when the iPs cells 
were cultured in conditions supporting differentiation into fetal liver-derived definite 
hematopoietic cells, the trisomic iPs cells showed an increase in multi-lineage colony forming 
potential (Maclean et al., 2012). There was no difference between trisomic iPS cells and 
disomic iPs cells when assessed in conditions appropriate for generating erythroblast co-
expressing fetal and embryonic globin genes (Li et al., 2012). These studies on iPS cells suggest 
that the influence of the additional chromosome 21 on hematopoiesis is dependent on the 
hematopoietic microenvironment.   
Multiple DS mouse models were used to examine the hematopoietic phenotype 
induced by trisomy 21. The Tc1 mice are a transchromosomic line which carries a freely 
segregating copy of human chromosome 21 (Wiseman et al., 2009). These mice present with 
macrocytic anemia together with an increased number of megakaryocytes and in the elderly 
with signs of extramedullary hematopoiesis. Interestingly, major changes in frequencies of 
erythroid progenitors, myeloid progenitors and megakaryocytes were not seen in the fetal 
liver (Alford et al., 2010). Ts16 mice are trisomic for mouse chromosome 16, which is synthetic 
of human chromosome 21 (Epstein et al., 1985; Gropp et al., 1974; Vacano et al., 2012). The 
Ts16 mouse line showed reduced myelopoiesis and increased erythropoiesis during the 
embryonic period (Gjertson et al., 1999). These mice do not survive postnatally, therefore 
their defects in hematopoiesis during this period are uncertain. Ts1Rh, Ts1Cje and Ts65Dn 
mice are lines of euploid DS model mice that bear a region of mouse chromosome 16 which 
contains 33, 81 and 104 genes, respectively. The Ts1Rh mice showed thrombocytosis and 
anemia in adulthood. The number of B-cell progenitors was reduced in Ts1Rh mice and their 
bone marrow cells differentiated preferentially toward granulocytes and monocytes (Lane et 
al., 2014; Malinge et al., 2012). Except for an increase in the HSC population, no hematological 
abnormalities were observed in the embryonic stage of Ts1Rh mice. Disturbed erythropoiesis 
was found in Ts1Cje mice. However, they never developed myeloproliferative diseases or 
thrombocytosis (Carmichael et al., 2009).  In contrast, progressive myeloproliferative diseases, 
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defects of stem cell function and macrocytic anemia were seen in the Ts65Dn mice (Kirsammer 
et al., 2008). The hematological phenotypes of these studied DS model mice lines show 
partially overlapping features with those seen in DS patients, however none of the studied 
mice acquire Gata1 mutations or develop leukemia (Shimizu and Yamamoto, 2015). 
2.1. Transient myeloproliferative disorder 
Transient myeloproliferative disorder (TMD), or transient abnormal myelopoiesis 
(TAM), is a unique and complex preleukemic condition with a specific genetic background and 
a perturbance of fetal hematopoiesis, which affects 10% of neonates with DS. TMD usually 
presents right after birth (Klusmann et al., 2008; Massey et al., 2006; Muramatsu et al., 2008) 
and in most cases resolves spontaneously without intervention in the first few months of life, 
hence the description transient (Klusmann et al., 2008). Nevertheless, approximately 20% of 
TMD patients progress to AMKL in the first 4 years of life, therefore these patients have to be 
closely monitored in this given timeframe (Gamis et al., 2011; Klusmann et al., 2008; Lange et 
al., 1998; Massey et al., 2006).    
The majority of patients present with clinical symptoms and approximately 10% are 
asymptomatic (Klusmann et al., 2008). Hepatomegaly and splenomegaly are common features 
of this disorder, due to the fact, that blasts in TMD likely originate in the fetal liver (Klusmann 
et al., 2008). Rarely, liver fibrosis can occur with life-threatening consequences (Al-Kasim et 
al., 2002). Skin infiltrations in the form of a rash are another common presentation. Less 
frequent symptoms include pericardial effusions, pulmonary edema, ascites and hydrops 
fetalis (Al-Kasim et al., 2002; Zipursky, 2003). Morphological examination of the peripheral 
blood and the bone marrow usually reveals a myeloid-appearing blast population that can be 
quite heterogeneous and vary in number. Megakaryoblasts are commonly present, some with 
characteristic protruding cytoplasmic blebs, together with features of dyserythropoiesis. 
Various alterations in the level of white blood cells, thrombocytes and hemoglobin may be 
observed (Roy et al., 2009).   
Most TMD patients do not require chemotherapy. Nonetheless, symptomatic 
neonates with liver dysfunction or a high percentage of blasts in the peripheral blood, may 
profit from brief treatment with low doses of cytosine arabinoside (Klusmann et al., 2008; 
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Massey et al., 2006). The mortality rate of TMD is about 20% (Klusmann et al., 2008; Massey 
et al., 2006; Muramatsu et al., 2008; Zipursky, 2003). 
The clonal expansion of hematopoietic progenitors, resulting in TMD is exclusively 
associated with two molecular factors – the extra copy of chromosome 21 and mutations in 
the megakaryocyte-erythroid transcription factor gene GATA1. This unique leukemic 
predisposition, presented only in neonates with DS, or in phenotypically normal neonates with 
trisomy 21 mosaicism, or very rarely in patients with somatic trisomy 21 solely in the blast 
population, underlines the important role that trisomy 21 is believed to play in the 
pathogenesis of this condition. Moreover, somatic mutations in GATA1 result in the sole 
expression of a shorter isoform of GATA1, the so called GATA1s protein, while eliminating the 
expression of full-length GATA1. Additional genetic aberrations may be present, as was 
recently exemplified by the largest sequencing study of TMD and AMKL patients so far by 
Labuhn and colleagues (Labuhn et al., 2019). 
Due to the omnipresence of GATA1 mutations and trisomy 21 in TMD, both should be 
investigated and validated to achieve proper diagnosis. Mutations in GATA1 may also serve as 
useful markers to monitor MRD and TMD progression in individual patients. In the recent 
recommendations of the British Society for Haematology, DS-TMD was defined as the 
presence of >10% of blasts in the peripheral blood, together with a GATA1 mutation and/or 
clinical features of DS-TMD in a child with DS or mosaic trisomy 21 (Tunstall et al., 2018). 
The multi-step process of TMD progression into AMKL has provided an essential in vivo 
model to study myeloid leukemogenesis. Trisomy 21 together with acquired somatic 
mutations of the GATA1 gene in stem cells or hematopoietic progenitors initiate the process 
of transformation during prenatal hematopoiesis (Fig. 6). At birth, multiple clones harboring 
GATA1 mutations may be present. However, in most cases of overt TMD, one clone is 
predominant (Hitzler and Zipursky, 2005). TMD manifests itself before, or usually right after 
birth as a preleukemia, in most cases resolves spontaneously and may later on progress to 
full-blown leukemia. In the majority of cases, trisomy 21 together with GATA1s is sufficient to 
initiate TMD, were exonic variants are relatively rare (Labuhn et al., 2019). The progression 
into leukemia on the other hand occurs, when the GATA1-mutated cells acquire additional 
somatic aberrations. The secondary transforming events most frequently occur in genes 
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encoding signaling molecules (JAK/STAT pathway, RAS-RAF-ERK pathway, RUNX1, TP53…), 
epigenetic regulators (KANSL1, SUZ12, EZH2…) and members of the cohesin protein family 
(STAG2, RAD21, SMC1A, CTCF…) (Labuhn et al., 2019; Nikolaev et al., 2013; Walters et al., 
2006; Yoshida et al., 2013). 
2.2. Acute megakaryoblastic leukemia of Down syndrome 
A characteristic molecular signature of trisomy 21, GATA1 mutations and additional 
somatic aberrations, characterizes DS-AMKL (Bourquin et al., 2006; Gruber and Downing, 
2015). Together with better outcome, it distinguishes itself from non-DS AMKL which 
frequently harbors chimeric oncogenes of hematopoietic gene origin and in which outcome 
tends to be poor (Gruber and Downing, 2015). Virtually all cases of DS-AMKL occur in the first 




Figure 6: Multi-step model of leukemogenesis in TMD and AMKL (adapted from Crispino and 





3. GATA transcription factor family 
The GATA gene family consists of six members (GATA1-6) that are structurally related 
and function as master regulators of transcription in a tissue-specific manner (Bresnick et al., 
2012; Chlon and Crispino, 2012). Each transcription factor contains a C-terminal and an N-
terminal Cys4-type zinc finger. GATA1 plays together with GATA2 a major role in normal 
hematopoiesis. As mentioned above, when mutated in the cell context of trisomy 21, GATA1 
mutations lead to TMD and/or AMKL. When mutated in germline, GATA1 aberrations result 
in a wide range of hereditary sex-linked forms of anemias and thrombocytopenias (Crispino 
and Weiss, 2014; Millikan et al., 2011; Nichols et al., 2000). Somatic mutations of GATA2 can 
be associated with myelodysplastic syndrome or AML, germline mutations on the other hand 
lead to the GATA2 deficiency syndrome (Collin et al., 2015; Shiba et al., 2014). GATA1 and 
GATA2 regulate each other’s expression. First, GATA2 initiates the expression of GATA1 in 
early megakaryocyte-erythroid progenitor cells. In comparison, GATA2 gene expression is 
down regulated by GATA1, which additionally activates its own expression. This phenomenon 
is known as GATA factor switching (Kaneko et al., 2010). Balance between these two 
transcription factors is crucial for proper hematopoiesis. GATA3 is widely expressed. In the 
immune system it controls T-cell proliferation (Wang et al., 2013). Interestingly, common 
GATA3 variants have been linked with Ph-like ALL in children and with the risk of relapse 
(Perez-Andreu et al., 2013). The remaining members GATA4, GATA5 and GATA6 play a role in 
the cardiovascular system, mainly during heart formation and are recurrently mutated in 
patients with congenital heart disease (Peterkin et al., 2005; Wei et al., 2013).  
3.1. GATA1 in hematopoiesis 
The GATA1 gene is located on the short arm of chromosome X, consists of 6 exons and 
encodes the GATA-binding factor 1 protein, which has a transactivation domain (TAD) and two 
centrally located zinc-finger domains, the N-terminal zinc-finger (NZF) and the C-terminal zinc-
finger domain (CZF) (Fig. 7). It is expressed in megakaryocytes, erythroid cells, mast cells, 
basophils and also in Sertoli cells (Onodera et al., 1997a; Onodera et al., 1997b; Yamamoto et 
al., 1997). The NZF plays a role in stabilizing GATA1 during its binding to DNA and in the 
specificity of the binding (Fig. 8). It enables the binding of GATA1 to a number of binding sites. 
These binding sites contain a palindromic recognition sequence (Trainor et al., 1996). 
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Moreover, NZF recruits and interacts with FOG1, a key cofactor of GATA1 (Tsang et al., 1997) 
(Fig. 7, 8). The CZF is necessary for GATA consensus sequence (A/T)GATA(A/G) recognition and 
for proper DNA binding activity (Evans et al., 1988; Martin et al., 1989; Tsang et al., 1997; Wall 
et al., 1988; Yang and Evans, 1992). Moreover, it plays an important role in the interaction of 
GATA1 with transcription factors like PU.1 and Sp1 (Merika and Orkin, 1995; Rekhtman et al., 
1999). The N-terminally located 83 residues of TAD have a strong transactivation potential on 
reporter genes that contain the GATA binding consensus sequence (Martin and Orkin, 1990). 
The necessity of GATA1 in erythropoiesis was first demonstrated with Gata1-null mouse 
embryos, which died from anemia at E10.5-E11.5 (Fujiwara et al., 1996). Remarkably, a 
different effect of GATA1 loss has been observed in megakaryocytes, which proliferate 
extensively, but fail to differentiate (Shivdasani et al., 1997). Megakaryocytes lacking GATA1 
possess various abnormalities (Vyas et al., 1999). Moreover, GATA1 has been associated with 
the development of basophils (Nei et al., 2013), mast cells (Migliaccio et al., 2003), eosinophils 
(Hirasawa et al., 2002; Yu et al., 2002) and dendritic cells (Kozma et al., 2010).  
Friend of GATA 1 (FOG1), an important cofactor of GATA1 as its name suggests, is a 
zinc finger protein that plays an essential role in hematopoiesis by binding and interacting with 
GATA1, through the NZF domain (Fig. 8). This interaction seems to be indispensable for FOG1 
in order to fulfil its role in megakaryopoiesis (Chang et al., 2002). Interestingly, absence of 
Fog1 in mice causes embryonic lethality due to severe anemia (Tsang et al., 1998). A number 
of point mutations in GATA1 that result in benign hematological disorders have been 
identified. Some, most notably mutations in V205 (Nichols et al., 2000), D218 (Freson et al., 
2001; Freson et al., 2002) and G208 (Mehaffey et al., 2001), which lead to various forms of 
anemias and thrombocytopenias, affect the affinity of GATA1 for FOG1, without influencing 
binding to DNA (Fig. 8). Aberrations of the NZF, like for example R216W effect GATA1 binding 






Figure 7: Schematic representation of the GATA1 gene. Both GATA1 wild type (wt) and GATA1s 
(GATA1 short) are expressed in healthy hematopoietic cells. Frameshift mutations in the 
second exon lead to the sole expression of GATA1s, with the loss of expression of the longer wt 
isoform. GATA1s lacks the transactivation domain (TAD). N-terminal zinc finger (NZF), C-
terminal zinc finger (CZF) (Lukes et al., 2020). 
 
Figure 8: Benign hematological disorders frequently harbor mutations affecting the N-terminal 
zinc finger (NZF) of GATA1 (adapted from Crispino and Horwitz, 2017) 
 
3.2. GATA1 mutations in TMD and AMKL 
Healthy human hematopoietic cells express two types of the GATA1 protein. The full-
length GATA1 and an alternative splicing variant, which originates from skipping of the second 
exon and is identical to GATA1s found in TMD and lacks the 83 N-terminal amino acids, which 
encode for TAD (Shimizu and Yamamoto, 2015; Wechsler et al., 2002). It utilizes an alternative 
translation initiation codon (Met84) in the third exon, instead of the translation initiation 
codon used by GATA1 full-length in exon 2 (Fig. 7) 
In TMD and DS-AMKL somatic mutations in GATA1 result in the exclusive production 
of GATA1s, nullifying the expression of GATA1 full-length (Fig. 7). Mutations, usually in the 
form of frameshift and nonsense mutations in the second exon, lead to an introduction of a 
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premature stop codon or possibly to the loss of the adjoining splice site (Alford et al., 2011). 
On a large cohort of DS patients using targeted NGS, Roberts and colleagues showed that 30% 
of patients with DS harbor GATA1 mutations. Interestingly, only one-third of them had clinical 
and hematological findings, which correlates with the previously published studies that 
suggest a 10% occurrence of TMD in DS (Roberts et al., 2013).  
Transgenic mice expressing GATA1s have been established in the past to investigate 
the function of GATA1s in vivo. Transgenic expression of GATA1s rescued males deficient for 
GATA1 from embryonic lethality (Shimizu et al., 2001). Interestingly, an accumulation of 
immature megakaryocytes was observed in fetal liver of the rescued mice (Shimizu et al., 
2009). However, this phenotype disappeared after birth, pointing to the fact that in mice 
GATA1s can provoke a TMD-like condition regardless of trisomy of chromosome 16, which 
serves as an equivalent to the human chromosome 21 (Shimizu et al., 2009). Transgenic mouse 
lines expressing low or high levels of GATA1s have been assessed for rescue analysis. 
Interestingly, low levels of GATA1s predisposed the mice to developing leukemia, while high 
levels of GATA1s never led to leukemia development in the studied mice (Shimizu and 
Yamamoto, 2015). Gene targeting has led to the establishment of mouse lines expressing 
GATA1 which lacked the 63 N-terminal amino acids (Li et al., 2005). This mouse model showed, 
that GATA1s leads to a hyperproliferation of a unique population of fetal liver progenitors and 
doesn’t affect the adult hematopoiesis (Li et al., 2005). Another mouse model was created by 
deleting the second exon of GATA1 (Gata1Δe2), leading to exclusive production of GATA1s in 
the Gata1Δe2 mice, also causing a transient hyperproliferative phenotype of the early 
embryonic megakaryocytes (Li et al., 2005). The here described models support the 
postulation that GATA1s alone causes the hypeproliferation of fetal liver megakaryocytic 
progenitors in mice (Li et al., 2005; Shimizu et al., 2009; Shimizu and Yamamoto, 2015). This 
observation was later validated in a CRISPR/Cas9 model of TMD in human fetal HSPCs 
(Gialesaki et al., 2018). Altogether, evidence clearly suggests that TMD initiates during fetal 






4. JAK/STAT signalling pathway 
The Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway 
plays a key role in hematopoiesis, growth, cell differentiation and immunity by mediating 
signals of more than fifty cytokines, hormones and growth factors (Constantinescu et al., 2013; 
Ihle, 1995; Rawlings et al., 2004; Schindler et al., 2007; Schindler, 2002; Villarino et al., 2015). 
There are four members in the JAK family: JAK1, JAK2, JAK3 and Tyk2. These intracellularly 
located, receptor associated, non-receptor protein tyrosine kinases are activated by receptor 
multimerization after ligand-binding (Haan et al., 2006; Ihle and Kerr, 1995). Activated JAKs 
phosphorylate their constitutively associated receptors and most importantly the STAT 
molecules, which consequentially dimerize and are trafficked into the nucleus, where they 
bind to specific DNA sequences and regulate target gene transcription (Becker et al., 1998; 
Chen et al., 1998; Darnell, 1997; Horvath and Darnell, 1997) (Fig. 9).  
 
Figure 9: JAK/STAT signalling pathway (adapted from Heinrich et al., 2003 and Haan et al., 
2006). Y (Tyrosine residues), P (phosphorylation). 
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JAKs consist of four domains, the N-terminally located FERM-domain, SH2-like domain, 
pseudokinase domain and a C-terminally located signalling protein kinase domain, that is 
catalytically active (Fig. 10). The two-faced god Janus gave JAKs their name, due to its 
resemblance with the two kinase domains that are present in JAKs. The JAK-receptor 
interaction is mediated by the FERM domain and the SH2-like domain (Radtke et al., 2005; 
Zhao et al., 2009), which also seem to play a role in JAK kinase activity regulation (Zhao et al., 
2010). The pseudokinase domain, shares a similarity with other kinase domains, like with the 
adjacent tyrosine kinase domain, but lacks crucial residues and therefore remains catalytically 
inactive. Nevertheless, it is believed to play a critical role in regulating the JAK kinase domain 
(Saharinen et al., 2000; Toms et al., 2013). 
 
 
Figure 10: Domain organization of the JAK1 protein (Lukes et al, 2020) 
 
4.1. JAK mutations in hematology 
Aberrant activation of JAK/STAT signalling plays a major role in hematological 
malignancies. Mutations in the JAK family are usually point mutations and are often associated 
with inferior prognosis (Flex et al., 2008). Interestingly, somatic gain of function mutations are 
most frequently located in the pseudokinase domain (Haan et al., 2010).  
Somatic JAK1 mutations occur recurrently in both childhood and adult acute leukemias 
(Jeong et al., 2008; Zhang et al., 2012). In adults they are present in about 20% of T-cell 
precursor ALL and have been linked to poor prognosis and response to therapy (Flex et al., 
2008). JAK1 mutations are less common, but still recurrent, in B-cell ALL (Mullighan et al., 
2009c), T-cell prolymphocytic leukemia (Bellanger et al., 2014) and in AML (Xiang et al., 2008). 
The aberrations are usually located in the pseudokinase domain, as for example the V658F 
mutant (Flex et al., 2008; Jeong et al., 2008), that has been proven as activating (Staerk et al., 
2005) and is an equivalent to the frequent and well-studied JAK2 V617F. The crystal structure 
of the JAK1 pseudokinase mutant V658F has served as a model for deciphering the role of the 
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pseudokinase in JAK activation. It has been postulated that three residues, Val658, Phe575 
and Phe636, termed as the F-F-V triad, play an important role in this process (Toms et al., 
2013). The triad is highly conserved and seems to be evolutionarily coupled. If Val658 is 
mutated into Phe658, as in the JAK1 V658F mutant, upon activation the Phe658 displaces 
Phe575, causing a switch resulting in the rearrangement of the SH2-PK linker (Fig. 11). 
 
 
Figure 11: The pseudokinase domain in JAK1 wild type (blue) and in the JAK1 V658F mutant 
(grey). A conformation switch can be observed in JAK1 V658F, with the displaced F575 residue.  
 
JAK2 mutations, which are associated with rearrangements of CRLF2 (Mullighan et al., 
2009a), are present in 20% of B-ALL patients with DS (Gaikwad et al., 2009; Kearney et al., 
2009) and in a lesser extent also in non-DS patients (Mullighan et al., 2009c). Importantly, JAK2 
mutations have been tightly linked with myeloproliferative neoplasms (Baxter et al., 2005). 
The substitution of valine 617 to phenylalanine (JAK2 V617F) is present in more than 90% of 
patients with polycythemia vera (James et al., 2005; Kralovics et al., 2005) and in 50% of 
patients with essential thrombocythemia and primary myelofibrosis (Levine et al., 2005). It is 
a gain of function mutation that is thought to activate JAK2 by the same conformation switch 
as described above on the JAK1 V658F mutant (Fig. 11). In this case the three crucial residues 
are represented by V617, F537 and F595 (Bandaranayake et al., 2012; Leroy et al., 2016; Toms 
et al., 2013). In vitro, JAK2 V617F induced cytokine independent growth (James et al., 2005) 
and a myeloproliferative-like disorder in vivo in mouse models (Lacout et al., 2006).  
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Mutations in JAK3 have been associated with T-ALL (Zhang et al., 2012), adult T-cell 
leukemia and lymphoma (Elliott et al., 2011; Kameda et al., 2010) and also with TMD and 
AMKL (De Vita et al., 2007; Kiyoi et al., 2007; Malinge et al., 2008; Riera et al., 2011; Walters 






The aim of this Ph.D. study was to identify and subsequently characterize novel genetic 
aberrations in childhood acute leukemias. 
1. To elucidate the alternative pathogenic mechanism of TMD development in the absence 
of trisomy 21. 
a. perform comprehensive genomic and transcriptomic profiling of a non-Down 
syndrome TMD.  
b. characterize the novel GATA1 D65_C228del mutation 
c. characterize the novel JAK1 F636del mutation 
d. study the impact of JAK1 F636del on GATA1s induced deregulation of erythroid and 
megakaryocytic lineage development in a murine TMD model 
2. To characterize two novel fusion gene, AIF1L-ETV6 and ABL1-AIF1L, in an ETV6-ABL1-
positive pediatric ALL and to describe the chromosomal rearrangement(s) that led to their 
formation. 
 a. thoroughly analyze the genomic profile of an exceptional ETV6-ABL1-positive ALL 
b. identify genomic fusion sites of the AIF1L-ETV6, ABL1-AIF1L and ETV6-ABL1 fusion 
genes 
c. characterize the chromosomal rearrangement(s) that led to the production of the 
fusion genes 
d. perform backtracking analysis in order to investigate the potential prenatal origin of 
the observed rearrangement(s). 
e. analyze potential AIF1L chimeric proteins 
3. To investigate the feasibility of genomic fusion identification and subsequent fusion-gene 
based MRD monitoring in patients harboring PML-RARA, CBFB-MYH11 or RUNX1-RUNX1T1. 





Total DNA and RNA was isolated from mononuclear cells that were separated by 
density centrifugation of patient’s diagnostic and remission bone marrow aspirates and 
peripheral blood samples as part of the routine sample processing procedure. The archived 
Guthrie card containing the patient’s neonatal blood was obtained from the national central 
repository. The study was approved by the Institutional Review Board of the University 
Hospital Motol and informed consent was obtained from patients’ parents in accordance with 
the Declaration of Helsinki. 
 
Single-nucleotide polymorphism assay (SNPa) 
Copy number aberrations (CNA) and regions of uniparental disomy (UPD) were 
analyzed using CytoScan HD array (Affymetrix, Santa Clara, CA, USA). The Chromosome 
Analysis Suite software (Affymetrix) was used for genotype calling, quality control, CNV/UPD 
identification and data visualization. Results were manually curated, deletions corresponding 
to somatic rearrangements of the immunoglobulin and T-cell receptor gene loci and common 
population variations were excluded. In case of the TMD patient a sample of peripheral blood 
containing 56% of blasts (as assessed by flow cytometry) was utilized for the analysis. For the 
patient with pre-BCP ALL, the SNPa analysis was performed as a service in the Laboratory for 
Molecular Biology and Tumor Cytogenetics at the Department of Internal Medicine of Hospital 
Barmherzige Schwestern (Linz, Austria). 
 
Analysis of acquired mutations and fusion transcripts by whole exome and whole 
transcriptome sequencing 
DNA and total RNA was used for sequencing libraries preparation using Agilent 
SureSelectXT HumanAllExon V5 and Agilent SureSelect mRNA Strand Specific kits, 
respectively, according to the manufacturer’s instructions (Agilent Technologies, Santa Clara, 
CA, USA). Read pairs were aligned to the human genome reference (hg19) using BWA (Li and 
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Durbin, 2010) (WES) and STAR (Dobin et al., 2013) (RNAseq) aligners and further processed by 
Picard tools (http://broadinstitute.github.io/picard/). VarScan (Koboldt et al., 2012) (WES) and 
Samtools (http://samtools.sourceforge.net/; RNAseq) were used for variant calling. Variants 
detected in remission samples were excluded from the analysis. TopHat (Kim and Salzberg, 
2011) and deFuse (McPherson et al., 2011) algorithms were used for the analysis of presence 
of fusion transcripts in RNAseq data.  
In the case of the trisomy 21-independent TMD patient the peripheral blood sample 
containing 56% of blasts was utilized for RNA isolation and subsequent RNAseq. DNA for WES 
was isolated from blasts that were sorted based on their immunophenotype by a fluorescence 
assisted cell sorter (FACS). WES was also performed on DNA isolated from non-tumor cells 
(FACS-sorted peripheral blood B and T lymphocytes) to facilitate the identification of somatic 
tumor-specific SNV and indels. Identified mutations were confirmed by Sanger sequencing and 
were annotated using the following NCBI transcript reference sequences: GATA1 – 
NM_002049.4, JAK1 – NM_002227.2, FN1 – NM_212482.1, SPIRE2 – NM_032451.1. 
 
Fusion gene screening 
 The BCR-ABL1, ETV6-RUNX1, KMT2A-AFF1 and TCF3-PBX1 fusions were screened by 
in-house developed multiplex reverse transcription PCR (RT-PCR). This was done as part of the 
routine molecular genetic diagnostics. A single PCR reaction, which combined primers for all 
four fusion, enabled the amplification of the ETV6-ABL1 fusion. 
 
Identification of genomic fusion sites  
Long distance PCR was performed using AccuPrime™ Taq DNA Polymerase (Thermo 
Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. A series of 
primers annealing to various regions of the respective introns of ETV6, ABL1 and AIF1L were 





Backtracking of the ETV6-ABL1 fusion in archived neonatal blood (Guthrie card)  
The specific detection of the ETV6-ABL1 genomic fusion was performed with the 
following PCR primers: 




The DNA from the patient’s diagnostic bone marrow sample was serially diluted into 
control healthy DNA and was used for the optimization of PCR conditions and to assess proper 
sensitivity. This initial optimization allowed us to achieve a sensitivity of 0.001%. The final PCR 
reaction included 12.5 µl of 2x SureDirect Blood PCR Master Mix (Agilent, Santa Clara, CA, 
USA), 1 µl of each primer (10 µM) and 2.5 µl MgCl2 (25 µM). The final reaction volume was 25 
µl. The cycling conditions were as follows: 5 min at 90oC; 14 cycles at 95oC for 30 sec, 65oC for 
30 sec (-0.5oC each cycle), and 72oC for 1 min; 40 cycles at 95oC for 30 sec, 58oC for 30 sec, and 
72oC for 1 min; 72oC for 5 min. Guthrie card segments (1/12 of blood spot) with the archived 
patient’s neonatal blood were directly added to the PCR tube. Guthrie card segments of the 
corresponding size, but without any blood, were added into the PCR tubes with positive 
control. The positive control tubes contained diluted patients diagnostic DNA. This was done 
in order to demonstrate the actual sensitivity of this assay which could potentially be 
compromised by Guthrie card material presence. The PCR products were finally analyzed by 
Sanger sequencing.  
 
Cloning 
Cloned AMV First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific) was used for 
RNA transcription into cDNA. PCR-amplified whole coding sequences of GATA1 wt, GATA1 
D65_C228del and JAK1 wt were cloned into a pWCC19 vector. InFusion HD Cloning Kit 
(Clontech, Takara Bio, Japan) was used for cloning. Sanger sequencing was used for the 
analysis of inserted coding sequences. pWCC19 vector-based constructs of JAK1 V658I, JAK1 
K908G, JAK1 F636del, JAK1 F636del+K908G and GATA1 M1V (resulting in GATA1s) were 
generated from respective wild type constructs using QuikChange Lightning Site-Directed 
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Mutagenesis kit (Agilent, Santa Clara, CA, USA). Primers used for the PCR reactions are listed 
below.  
 
Primers used for amplification from cDNA and for cloning (5’ to 3’) 
JAK1 forward: GTCGACCTCGAATCGGATCCGAACACTGGACAGCTGAATAAATGC 
JAK1 reverse: AGATTCCTGCAGCCCGGGCAGGAGAAGGACTTGATAATCTGTGG 
GATA1 forward: GTCGACCTCGAATCGGATCCAGGTTAATCCCCAGAGGCTCC 
GATA1 reverse: AGATTCCTGCAGCCCGGGCATGCTCTGTGCCCTCATGAG 
 
Primers used for mutagenesis (5’ to 3’) 
JAK1 K908G forward: GGAGCAGGTGGCTGTTGGATCTCTGAAGCCTG 
JAK1 K908G reverse: CAGGCTTCAGAGATCCAACAGCCACCTGCTCC 
JAK1 F636del forward: GGATATTTCCCTGGCCTTCGAGGCAGCCAGCATGATGAG 
JAK1 F636del reverse: CTCATCATGCTGGCTGCCTCGAAGGCCAGGGAAATATCC 
JAK1 V658I forward: CCTCTATGGCGTCTGTATCCGCGACGTGG 
JAK1 V658I reverse: CCACGTCGCGGATACAGACGCCATAGAGG 
GATA1 M1V forward: CCCAGAGGCTCCGTGGAGTTCCCTGGCCTGG 
GATA1 M1V reverse: CCAGGCCAGGGAACTCCACGGAGCCTCTGGG 
 
ABL1-AIF1L, AIF1L-ETV6 and wild type AIF1L constructs were produced from total RNA 
isolated from the patient’s diagnostic bone marrow sample and from HEK293T cells. Cloned 
AMV First-Strand cDNA Synthesis Kit (Thermo Fisher Scientific) was used for reverse 
transcription of RNA. HEK293T cDNA was used for the amplification of full-length coding 
sequence of AIF1L wild type. The patient’s cDNA was used for the amplification of coding 
sequences of fusion transcripts ABL1-AIF1L and AIF1L-ETV6. InFusion HD Cloning Kit (Clontech) 
was used for cloning of the PCR products into the pIRES2-EGFP vector. Inserted sequences 
were confirmed by Sanger sequencing.  
 
Primers used for amplification from cDNA and for cloning (5’ to 3’) 
AIF1L forward: CTCGCCATGTCGGGCG 
AIF1L reverse: CGGGGTCCTCAGGGCAG 
ETV6 reverse: GGTGGACTGTTGGTTCCTTCAGC 







Analysis of the AIF1L-ETV6 and ABL1-AIF1L fusion transcripts 
RT-PCR and subsequent Sanger sequencing verified the AIF1L-ETV6 and ABL1-AIF1L 
fusion transcripts identified by RNAseq. Fusion sequences from RNAseq served as bases for 
RT-PCR primer design: 
Primers used for RT-PCR (5’ to 3’) 
AIF1L-ETV6 forward: GCAGCTACAGAGGATTTCATGTTCC 
AIF1L-ETV6 reverse: CATAGGTCATGTTTGTTCTGTTCTTATGG 
ABL1-AIF1L forward: CTCTACGCTCGCTGACCGTTC 
ABL1-AIF1L reverse: TGAGGACAGCCGACCGTTTC 
 
The same PCR systems were used for the analysis of the presence of these particular 
fusion transcripts in 10 ETV6-ABL1-positive leukemia patients collected during our previous 
study (Zaliova et al., 2016). 
 
Cultivation and transient transfection of HEK293T cells and NIH cells 
The HEK293T (human embryonic kidney carcinoma) and NIH3T3 (murine fibroblast) 
cell lines were kindly provided by the Tenen lab (Harvard Medical School). The cell lines were 
cultivated in Dulbecco’s Modified Eagle Medium (DMEM; Thermo Fisher Scientific) 
supplemented with 10% of heat-inactivated fetal bovine serum (FBS; Biosera, Nuaille, France) 
and Antibiotic-Antimycotic (Thermo Fisher Scientific). Lipofectamine 2000 (Thermo Fisher 




RIPA buffer was used to prepare whole cell extracts. NE-PER Nuclear and Cytoplasmic 
Extraction Reagents (Thermo Fisher Scientific) supplemented with Complete Protease 
Inhibitor Cocktail (Roche, Basel, Switzerland) were used to extract nuclear and cytoplasmic 
protein lysates. Proteins were resolved by the Bolt 4–12% Bis-Tris Plus protein gels (Thermo 
Fisher Scientific). The resolved proteins were transferred onto a nitrocellulose membrane 
(Bio-Rad, Hercules, CA, USA). Non-specific binding was blocked with phosphate-buffered 
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saline containing 0.1% Tween 20 (Bio-Rad) and 5% dry milk for 1 hour. The following primary 
antibodies were used for immunoblotting: GATA1 (ab11852, 1:500, Abcam, Cambridge, UK), 
Jak1 (sc-376996, 1:500, Santa Cruz, Dallas, TX, USA), p-Jak1 (Tyr1034/1035, 74129, 1:1000, 
Cell Signaling, Danvers, MA, USA), TBP (ab63766, 1:1000, Abcam), GAPDH (G8795, 1:10000, 
Sigma-Aldrich), Stat3 (sc-8019, 1:500, Santa Cruz), p-Stat3 (Tyr705, 9145, 1:1000, Cell 
Signaling). Primary antibodies against the N-terminus of AIF1L (HPA056852; 1:500, Sigma-
Aldrich) and the C-terminus of AIF1L (HPA020522; 1:250, Sigma-Aldrich). Incubation with the 
primary antibody was done overnight. The primary protein bound antibodies were detected 
with an appropriate secondary antibody, which was conjugated with horseradish peroxidase 
and Super Signal West Pico Chemiluminescent Substrate kits (Thermo Fisher Scientific). 
Visualization was performed using an ECL system (Bio-Rad). 
 
Lentivirus production 
HEK293T cells were used for lentivirus production. pWCC19 vectors together with 
packaging plasmids (p-gag-pol, p-VSV-G) were co-transfected into the cells using Xfect 
Transfection Reagent (Clontech). Centricon Plus-70 Centrifugal Filter Devices (Merck 
Millipore, Burlington, MA, USA) were used for the concentration of the collected 
supernatants. Virus titer was assessed in the NIH3T3 cell line. 
 
Ba/F3 cell proliferation 
Ba/F3 cells were purchased from DSMZ (ACC 300). They were cultured in RPMI 
(Thermo Fisher Scientific) with 10% FBS, 10µg/ml interleukin 3 (IL3; Sigma-Aldrich, St. Louis, 
MO, USA) and Antibiotic-Antimycotic. Transduced Ba/F3 cells positive for GFP were sorted. 
For the IL3 withdrawal experiments Ba/F3 cells transduced by JAK1 
F636del/F636del+K908G/V658I/JAK1 wild type or the empty vector were washed with PBS 3 
times. Then they were cultured in the absence of IL3 for 10 days. Cells were counted every 




TF1 cell proliferation 
TF1 (human erythroleukemia) cells were transduced with JAK1 F636del/JAK1 wild 
type/GATA1 D65_C228del/GATA1 M1V/GATA1 wild type or empty vector. The target 
transduction efficiency was 10%. After 72 hours cells were split into two populations. The 
control population was cultured in the presence of 5ng/ml of human recombinant granulocyte 
macrophage-colony stimulation factor (GM-CSF). The second cell population was washed 3 
times with PBS and cultured in the absence of GM-CSF. Cell proliferation was monitored by 
assessing GFP positivity. 
 
K562 cell assay 
The K562 (chronic myeloid leukemia in blast crisis) cell line was transduced with GATA1 
D65_C228del/GATA1 M1V/GATA1 wild type or empty vector. Transduction efficiency was 
assessed by GFP-positivity. The cells were stimulated with 10ng/ml Phorbol-12-myristate-13-
acetate (PMA) to induce differentiation. Dimethylsulfoxid (DMSO) served as control. Flow 
cytometry analysis was conducted 1, 2 and 3 days after stimulation.  
 
Human adult CD34-positive HSPC assay 
Human CD34-positive adult hematopoietic stem and progenitor cells (HSPCs) were 
isolated from peripheral blood samples of healthy donors. The cells were transduced with 
GATA1 D65_C228del/GATA1 M1V/GATA1 wild type or empty vector. Differentiation was 
induced by change of media two days after transduction. The differentiation media included 
5ng/ml stem cell factor (SCF), 5ng/ml GM-CSF, 10ng/ml granulocyte-colony stimulating factor 








Murine bone marrow was extracted from long bones and hips of C57BL/6J mice by 
crunching. Murine fetal liver cells were isolated from E13.5 mouse embryos. Erythrocytes 
were lysed using ACK buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
ethylenediaminetetraacetic acid). Biotinylated anti-CD117 antibody was used for c-kit+ cells 
staining. Cells were separated from the bone marrow using Anti-Biotin MicroBeads UltraPure 
(Miltenyi Biotec, Bergisch Gladnach, Germany) by MACS. The c-kit+ cells were lentivirally 
transduced with JAK1 F636del/JAK1 wild type or empty vector. Transduced cells were 
expanded for 48 hours in IMDM with 15% FBS, mSCF, mIL3, mIL6 (Peprotech, Rocky Hill, NJ, 
USA). Transduced c-kit+ GFP expressing cells were sorted and seeded in MethoCult GF M3434 
medium (Stemcell Technologies, Vancouver, BC, Canada). Microscopy was used for counting 
and classification of the cell colonies. 
 
Competitive growth assay of Gata1s-positive mouse fetal liver cells. 
Ter119 depleted fetal liver cells were isolated from E13.5 Cas9 knock-in mouse 
embryos. Cells were transduced with a Gata1-sgRNA expression vector. Transduced cells were 
cultured under low cytokine conditions for the duration of 3 weeks. A population of 
transduced Gata1s cells was obtained by this selection as previously described (Labuhn et al., 
2019). Gata1s expression in these cells was confirmed by Western blot analysis. The Gata1s-
positive cells were transduced with JAK1 F636del/JAK1 wild type or empty vector. In one 
experimental setting the cells were simultaneously transduced with Gata1-sgRNA and JAK1 
F636del/JAK1 wild type. Double positive cells were measured every other day by flow 
cytometric analysis to assess their percentage. Cells were cultured either in a fully cytokine-
supplemented growth-supportive media (mSCF, mTPO) or in a cytokine-depleted growth-
restrictive (only mSCF/only mTPO) media or in a media containing 0ng/ml / 0,1ng/ml / 1ng/ml 







JAK1 F636del models were generated by Modeller (Webb and Sali, 2016) using the 




Project 1. The alternative pathogenesis of TMD development in the absence 
of trisomy 21 
1. The identification of a trisomy 21-independent TMD questions the indispensability of 
trisomy 21 in the pathogenesis of this preleukemic condition. 
We have identified a unique TMD with a typical clinical and morphological 
manifestation (Table 1, Fig. 1-2) in a newborn without the features of Down syndrome. 
Immunophenotypic analysis of the peripheral blood, performed by flow cytometry, revealed 
56% of atypical cells (Fig. 3-4). We compared the expression levels of selected antigens on the 
gated blast cells population from the non-DS-TMD with expression levels in DS-TMDs and with 
AMKL cases diagnosed and treated at our department. The non-DS-TMD exhibited an 
immunophenotype that differed from the DS-TMDs, particularly by a high expression of the 
CD61 and CD41 antigens and a weak expression of the CD33 antigen, resembling more an 
immunophenotype of AMKL (Fig. 3-4). Due to critical clinical manifestation, advanced 
symptomatic treatment was initially required. However, during the intensive 2-week 
treatment period after diagnosis (after birth) the clinical picture gradually improved and no 
chemotherapeutics were therefore administered. Due to the spontaneous remission of the 





Table 1 (previous page): Typical clinical and hematological features of DS-TMD (* based on 
data from Klusmann et al., 2008; Roberts et al., 2013; Tunstall et al., 2018) were also found in 
the here presented non-DS-TMD, exemplifying the clinical and hematological similarity of both 
entities. 
 
Figure 1: The examination of a bone marrow (top) and peripheral blood (bottom) smears 
identified blasts with prominent nucleoli, cytoplasmic blebs and a basophilic cytoplasm 
morphologically resembling megakaryoblasts. This finding is indicative of a TMD/AMKL. 
 
Figure 2. Signs of dyserythropoiesis in the bone marrow aspirate. The blue arrow shows one 
polychromatophilic erythroblast. The red arrow point an oxyphilic erythroblast. Its nucleus is 
atypically shaped with constrictions. The green arrows points to erythroblasts, whereas the 




Figure 3: The diagnostic cell immunophenotyping analysis revealed atypical blasts that were 
gated as a CD45dim subpopulation from the lymphomonocytic compartment (“wide 
lymphomono”). A strong expression of CD41 (91%), CD61 (86%), CD42 (67%), CD4 (87%) and a 
weak expression of CD38 (26%), CD7 (14%), CD33 (12%), CD71 (42%) and CD117 (17%) was 




Figure 4: The comparison of immunophenotypes in AMKL patients (n=7, blue circles) and DS-
TMD patients (n=15, black circles) treated at the University Hospital Motol (Department of 




Figure 5: MRD monitoring of the patients’ disease progression by quantifying GATA1 





2. Cytogenetic and SNP array analysis confirms absence of trisomy 21 and genomic profiling 
identifies novel potential drivers of the trisomy 21-independent TMD development. 
To exclude trisomy 21 involvement of the hematopoietic lineage, cytogenetic 
examination of the blast population was conducted. The FISH analysis of chromosome 21 was 
repeated twice and in both cases showed absence of trisomy 21. The examined blast cells had 
a normal male karyotype.  
High-density SNP array analysis was performed to detect copy number changes (Fig. 
6). Peripheral blood was used with a proportion of 56% of blasts (as assessed by flow 
cytometry). The analysis reliably excluded presence of whole-chromosome or partial trisomy 
21 in the blasts. 
We performed a comprehensive review of literature to establish if other trisomy 21-
independent cases have been identified. All of the non-Down syndrome TMD cases that were 
described so far, harbored trisomy 21 in the blast population (Table 3). To the best of our 
knowledge the presented non-DS-TMD is the first described case of trisomy 21-independent 
GATA1-mutated TMD.  
To elucidate the alternative pathogenesis of this exceptional TMD without trisomy 21 
involvement we performed whole exome and whole transcriptome sequencing. We found in-
frame deletions in the JAK1 and GATA1 genes and missense mutations in the SPIRE2 and FN1 
genes (Table 2). All genetic aberrations were confirmed by Sanger sequencing.  
JAK1 mutations are implicated in a number of hematological malignancies including 
TMD and AMKL. On the other hand SPIRE2 and FN1 are genes that do not have an established 





Figure 6: CNA analysis by SNP array. No aberrations were observed by CNA on any 
chromosome. No gain of chromosome 21 or its part was detected. Some regions with changed 
copy number are noticeable, mainly in the upper graph. These correspond to array specific 
artefacts and common population polymorphisms.  
 
 
Table 2: Novel genetic aberrations discovered by WES which was performed using DNA from 





Table 3 (next page): Literature review of non-Down syndrome TMD patients. M (male), F 







3. The novel GATA1 deletion, GATA1 D65_C228del, results in the expression of an internally 
truncated protein lacking the entire N-terminal zinc finger domain. 
All TMD patients harbor mutations in the GATA1 gene usually represented by small 
insertions, duplications and deletions which cluster in the second exon. These aberrations lead 
to the introduction of a premature stop codon or to the loss of an adjoining splice site and 
finally result in the exclusive production of a shorter version of GATA1, the GATA1s protein, 
which lacks the transactivation domain (Fig. 7-8). The novel GATA1 aberration, GATA1 
D65_C228del, described in the trisomy 21-independent TMD presented here, causes a 
deletion of 1106 base pairs (bp) and an insertion of 9 bp spanning between the second and 
forth exon. The deletion is in-frame and results in the expression of an internally truncated 
protein. This protein lacks part of the TAD and more importantly also the whole N-terminal 
zinc finger (Fig. 7-8). 
To elucidate if the aberrant protein is expressed, we cloned the full-length cDNA of 
GATA1 wt, GATA1s and GATA1 D65_C228del into lentiviral vectors. The GATA1s expressing 
construct was prepared by introducing a M1V mutation in the canonical start codon of GATA1. 
We studied the expression of GATA1 D65_C228del chimeric protein in HEK293T cells. The 
presence of GATA1 proteins in transiently transfected HEK293T cells was analyzed using a 
polyclonal anti-GATA1 antibody. We confirmed the expression of the GATA1 D65_C228del 
protein and showed that it is trafficked into the nucleus, similarly to the physiological isoforms 






Figure 7: Schematic representation of the GATA1 gene. The upper model shows physiological 
production of GATA1 in a healthy individual where both GATA1 wt and GATA1s are expressed. 
The model in the middle represents the situation in trisomy 21-positive TMD patients were due 
to mutations in the second exon, exclusively GATA1s is expressed. The bottom diagram shows 
the novel mutation described in the presented patient, resulting in the production of an even 
shorter GATA1 variant. bp (base pair), del (deletion), ins (insertion), TAD (transactivation 
domain), NZF (N-terminal zinc finger), CZF (C-terminal zinc finger). 
 
Figure 8: Western blot analysis of GATA1 wt, GATA1s and GATA1 D65_C228del expressing 
HEK293T cells. Different protein sizes are nicely visible. Protein separation into the cytoplasmic 
(C) and nuclear (N) fractions shows that all three transiently expressed proteins are trafficked 
into the nucleus. TBD and GAPDH serve as loading controls. EV (empty vector), kDa (kilodalton) 
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4. Searching for a model to study the effect of GATA1 D65_C228del on megakaryocytic and 
erythroid differentiation. 
First, we decided to study the effect of GATA1 D65_C228del on megakaryocytic and 
erythroid differentiation in the human K562 erythroleukemia cell line. The K562 cell line has 
served as a valuable model for the study of mechanisms associated with the differentiation of 
leukemic cells (Jacquel et al., 2006; Lam et al., 2000; Racke et al., 2001; Rainis et al., 2005) and 
to study the role of GATA1 in hematopoiesis (Halsey et al., 2012; Huang et al., 2005; 
Matsumura et al., 2000). Most importantly, the K562 cells have been previously used to 
compare the effects of GATA1 wt and GATA1s (Halsey et al., 2012).  The K652 cells express, in 
undifferentiated conditions, markers of both megakaryocytic and erythroid lineages. 
Depending on the stimulus, they can undergo further differentiation.  Phorbol-12-myristate-
13-acetate (PMA) stimulates K562 cells to undergo megakaryocytic differentiation (Dorsey et 
al., 2002; Huang et al., 2014; Kim et al., 2001; Pettiford and Herbst, 2003; Shelly et al., 1998). 
The PMA-induced megakaryocytic differentiation partially mimics the physiological processes 
that occur in the bone marrow (Long et al., 1990). The differentiation is accompanied by 
expression of specific megakaryocytic markers like CD61 and CD41, together with changes in 
morphology (Jacquel et al., 2006). 
We introduced the empty vector (EV), GATA1 wt, GATA1s and GATA1 D65_C228del 
constructs into the K562 cells. A high (>90%) and similar transduction efficiency, measured by 
GFP positivity, was achieved with all four constructs (Fig. 9). Megakaryocytic and erythroid 
differentiation was induced two days after transduction by 10ng/ml of PMA. Dimethylsulfoxid 
(DMSO) served as control. Flow cytometry analysis was conducted one, two and three days 
after stimulation by measuring megakaryocytic (CD41, CD42b) and erythroid (CD235a, CD71) 
surface markers (Fig. 9). DAPI was used to distinguish viable from non-viable cells. 
We hypothesised that introduction of GATA1 wt will allow the cells to differentiate 
into the megakaryocytic linage, whereas GATA1s introduction will decelerate or even arrest 
this differentiation as previously described (Halsey et al., 2012). Moreover we expected to see 
a similar or stronger effect induced by the GATA1 D65_C228del as compared to GATA1s. The 
PMA stimulation was successful. However, no difference between the GATA1 wt, GATA1s and 
GATA1 D65_C228del constructs in the expression of both erythroid and megakaryocytic 
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markers was visible (Fig. 10). We were not successful in optimizing the model. The lack of 
variation between GATA1 wt and GATA1s deemed this approach inappropriate for our usage. 
Next, we conducted a similarly designed experiment on human CD34 positive adult 
hematopoietic stem and progenitor cells (HSPCs) isolated from peripheral blood samples. The 
cells were transduced with lentiviral empty vector, GATA1 wt, GATA1s and GATA1 
D65_C228del constructs. Differentiation was induced by change of media two days after 
transduction. Myeloid (CD14, CD15), erythroid (CD71, CD235a) and megakaryocytic (CD41) 
differentiation was assessed by flow cytometry five and nine days after stimulation. 
Unfortunately, no difference was apparent between GATA1s and GATA1 D65_C228del, except 
for a slight difference in the expression of CD41, therefore making this model also unfit for 
assessing the impact of GATA1 D65_C228del (Fig. 11). 
 
 





Figure 10: The expression of CD41, CD45b, CD71 and CD235a+ in lentivirally transduced K562 





Figure 11: The expression of CD71, CD235a, CD41, CD14 and CD15 in lentivirally transduced 





Finally, we attempted to study the differences between GATA1s and GATA1 
D65_C228del in the human erythroleukemia cell line TF1, which is dependent on GM-CSF and 
was at our disposal.  This model has been previously used to assess the functionality of the 
CSF2RB A455D variant (Labuhn et al., 2019). The TF1 cells were transduced with GATA1 wt, 
GATA1s and GATA1 D65_C228del constructs, aiming for 10% transduction efficiency. Cells 
were cultured either with or without human GM-CSF. Cells harboring either GATA1 wt, 
GATA1s or GATA1 D65_C228del ceased to proliferate in both cytokine rich and cytokine free 
conditions, demonstrating the inapplicability of this model to study differences between 
GATA1 variants (Fig. 12). 
 
Figure 12: Transduced TF1 cells (with GATA1 wt, GATA1s or GATA1 D65_C228del) cultured in 
the presence (left panel) or absence (right panel) of GM-CSF. 
 
5. The novel JAK1 mutation is located in a crucial part of the pseudokinase domain. 
 The identified novel mutation is located in the pseudokinase domain of JAK1, which is 
a hotspot region for activating mutations (Flex et al., 2008; Haan et al., 2010; Jeong et al., 
2008) (Fig. 13). JAK mutations have been described previously as drivers in hematological 
malignancies, including AMKL (Chen et al., 2012; Labuhn et al., 2019). The deletion results in 
the loss of phenylalanine 636 (F636del) which is a highly conserved aminoacid among various 
species (Fig. 14). Moreover, it belongs to a highly conserved triad of aminoacids, namely V658, 
F636, F575, which is believed to control JAK1 catalytic activity by mediating a conformation 
switch between the active and inactive forms (Toms et al., 2013). Therefore JAK1 F636del 
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seemed as the likely candidate for a driver mutation that could cooperate with GATA1 
D65_C228del on TMD induction without the involvement of trisomy 21. 
 
Figure 13: Schematic representation of the JAK1 protein and its domain organization. The 
brown arrow highlights the deletion of F636 which is located in the pseudokinase domain. The 
red arrow highlights a known activating mutation V658I, the blue arrow highlights an 
inactivating mutation in the kinase domain. V658I and K908G were used as controls.  
 
Figure 14: The comparison of the wild type and mutated allele F636del (shown in red) of the 
JAK1 gene. The nucleotides are denoted by capital letters and aminoacids in bolt, dashes 
indicate missing nucleotides/aminoacids. The comparison between various animal species 
points to a high conservation of the phenylalanine located on the 636 position in the JAK1 gene 
(shown in red).  
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We performed homology modeling of the mutated JAK1 pseudokinase domain which 
suggested that JAK1 F636del is compatible with both the active and the inactive conformation. 
Moreover, the mutated pseudokinase may adopt a third conformation. This alternative 
conformation, which was not achieved, or previously described, by the wild type JAK1 
pseudokinase, may potentially mimic the “inactive” state (Fig. 15). We hypothesized that the 
neighboring phenylalanine F635 could replace the deleted phenylalanine F636 in its vacant 
position. The modeling suggested otherwise. F635 of the mutated JAK1 F636del, in both the 




Figure 15: Homology modeling of the JAK1 pseudokinase domain. Three predicted 
conformations of the mutated pseudokinase domain (JAK1 F636del) were superposed with the 
JAK1 wild type structure (white; PDB entry 4L00; Toms et al, 2013) in the inactive 
(crystallographic molecule A; left panel) or active (crystallographic molecule A; middle and 
right panel) state. F575, F636, and V658 in JAK1 wild type are labelled. The modelling suggests 
that the SH2-PK linker (with F575 shown in red) of JAK1 F636del can adopt either an inactive 
(orange) or active (green), or an “alternative” (blue) conformation, the latter of which has not 





Figure 16: Homology modelling of JAK1 F636del in the active (orange) and inactive (green) 
conformation superimposed with JAK1 wild type (blue) showing the side chain of F635. 
 
6. JAK1 F636del does not activate the JAK1 kinase but rather attenuates its function. 
 We assessed the kinase activity of JAK1 F636del. In order to distinguish between auto- 
and trans-phosphorylation, we utilized side-directed mutagenesis and created a JAK1 
construct harboring an inactivating mutation of an ATP-binding site (K908G) and a construct 
harboring both the JAK1 F636del and K908G mutations together (Fig. 13). The JAK1 F636del, 
but not JAK1 F636del + K908G, was autophosphorylated on Y1034/Y1035 both under steady 
state conditions and after non-specific PMA stimulation (Fig. 17-19). 
JAK1 F636del induced STATs phosphorylation both in non-stimulated and stimulated 
HEK293T cells. However, all phosphorylation levels, at all studied time points were lower when 
comparted to wild type JAK1, except immediately after PMA stimulation, when STAT3 
phosphorylation was comparable between JAK1 F636del and JAK1 wt (Fig. 19) These data 




Figure 17: Western blot analysis of the kinase activity in HEK293T cells transiently transfected 
with empty vector (EV), JAK1 wt, JAK1 F636del or the catalytically deficient form (bearing the 
K908G mutation). Catalytic activity is preserved in JAK1 F636del which was 
autophosphorylated on Y1034/Y1035. GAPDH and TBP serve as loading controls. Cells were 
stimulated for 15 minutes with 1µg/ml PMA. Separated cytoplasmic (C) and nuclear (N) protein 
fractions were analyzed.  
 
 
Figure 18: Western blot analysis of the kinase activity in HEK293T cells transiently transfected 
with empty vector (EV), JAK1 wt, JAK1 F636del. Stimulation was carried out for 15 minutes with 
1µg/ml PMA. Cells were harvested and analyzed immediately after stimulation, 1 hour (h), 2h 




Figure 19: Western blot analysis of JAK/STAT signalling in transiently transfected HEK293T cells 
with empty vector (EV), JAK1 wt or JAK1 F636del. Lower levels of STAT3- and auto- 
phosphorylation when compared to JAK1 wild type suggest decrease in JAK1 F636del kinase 
activity. 
 
To assess the activating potential of JAK1 F636del, we utilized the well-known murine 
Ba/F3 cell transformation assay (Lacronique et al., 1997; Palacios and Steinmetz, 1985; 
Warmuth et al., 2007). For example, the activating potential of the JAK2 V617F mutation that 
is present in almost 90% of polycythemia vera patients has been validated via this assay (James 
et al., 2005). Similarly several novel JAK1 mutations were shown activating in this particular 
assay (Arulogun et al., 2017; Li et al., 2017). We used the previously described activating 
mutation JAK1 V658I as a positive control (Fig. 13) (Arulogun et al., 2017).  
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 Unlike V658I, JAK1 F636del did not induce IL3-independent growth in the Ba/F3 assay 
after 10 days of culture in a cytokine depleted environment (Fig. 20). Moreover, JAK1 F636del 
did not induce cytokine independent growth in the human TF1 cell line (Fig. 21). These data 
suggest, that F636del does not activate the JAK1 kinase but rather attenuates its function.  
 
Figure 20: The proliferation of Ba/F3 cells in an IL3 depleted medium shows identical 
proliferation rates of JAK1 F636del and JAK1 wt. The known activating mutation V658I serves 
as a positive control. Sorted Ba/F3 were cultured for 10 days in a cytokine deprived medium. 
Proliferation of the Ba/F3 cells was measured every other day. Dead cells were excluded with 
the use of trypan blue. EV (empty vector). 
 
 
Figure 21: Transduced TF1 cells (with empty vector, JAK1 wt or JAK1 F636del) cultured in the 
presence (left panel) or absence (right panel) of GM-CSF 
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Interestingly, we observed a confusing phenomenon of the Ba/F3 assay also recently 
described by Watanabe-Smith and colleagues (Watanabe-Smith et al., 2017). Strikingly, the 
JAK1 wild type which served as control in our Ba/F3 assay exhibited cytokine independent 
growth 15 days after IL3 depletion (Fig. 22A). Sequencing of the transformed JAK1 wild type 
expressing Ba/F3 cells revealed acquired, previously described, activating mutations L910P 
and S729C (Kan et al., 2013; Yang et al., 2016). Our data imply that similar unwanted 
transforming events can appear in wild type genes following Ba/F3 cell selection when 
cultured in a cytokine depleted medium for a longer time period. Therefore we propose that 
up to 5 days of culture can give results sufficiently accurate to evaluate the studied mutations 
transforming potential (Fig. 22B). Moreover transformed cells should always be sequenced, a 
practice not performed by all laboratories (Watanabe-Smith et al., 2017).   
 
 
Figure 22: A) Proliferation of Ba/F3 cells transduced with JAK1 wild type or empty vector, 
cultured either in an IL3 rich medium or in an IL3 depleted environment. Cells harboring the 
JAK1 wild type construct started proliferating independently of IL3 after 15 days in culture. B) 







7. The colony forming capacity of JAK1 F636del does not differ from wild type in both murine 
CD34+ bone marrow and fetal liver cells. 
 To further evaluate the phenotypic impact of JAK1 F636 loss, we introduced empty 
vector, JAK1 wt or JAK1 F636del into murine bone marrow HSPCs using lentiviruses. 
Transduced, GFP expressing c-kit positive cells were sorted and used for colony-forming unit 
(CFU) assays. There was no difference in the colony-forming capacity of JAK1 wt and JAK1 
F636del (Fig. 23A). To assess the cell morphology, the percentage of granulocytes, 
macrophages and immature cells was counted for each construct. There was no difference 
between the three constructs (Fig. 23B). 
 
Figure 23: A) Colony-forming unit assays in sorted murine CD34+ bone marrow HSPCs 
transduced with empty vector, JAK1 wt and JAK1 F636del.  B) Percentage of granulocytes, 
macrophages and immature cells in individual constructs.  
 
 Since TMD originates prenatally in the fetal liver we decided to mimic its 
microenvironment by using fetal liver HSCPs extracted from embryonic day 13.5 mouse 
fetuses. Transduced, GFP expressing c-kit positive cells were sorted and used for CFU assays. 
Even in this setting we did not observe any difference in colony-forming capacity between 




Figure 24: Colony-forming unit assays in sorted murine fetal liver HSPCs transduced with empty 
vector, JAK1 wt or JAK1 F636del. The number of colonies did not differ between the constructs 
in both the first and second plating.  
 
8. Mimicking trisomy 21-independent TMD in a murine fetal liver cell model to study the 
cooperation of JAK1 F636del and GATA1s. 
 Our results suggested that JAK1 F636del may exert its impact in TMD pathogenesis 
only in cooperation with mutated GATA1. Therefore the need for a more precise model was 
warranted.  We established a collaboration with Prof. Jan-Henning Klussman from the Martin-
Luther University in Halle, Germany. I conducted the here described experiments during a 3-
month stay in Prof. Klusmann’s laboratory. We utilized an in vitro model recently described by 
Prof. Klusmann and colleagues (Labuhn et al., 2019).  Induction of Gata1s expression in 
disomic fetal liver HSPCs from embryonic day 13.5 ROSA26:Cas9-EGFPki/wt mice was 
mediated by the CRISPR/Ca9 gene editing system. In this setting, Gata1s expression leads to 
the expansion and hyperproliferation of fetal liver HSPCs. A 3-week selection process under 
low levels of the cytokines thrombopoietin (TPO) and stem cell factor (SCF) facilitate the 
acquisition of a pure Gata1s positive cell population, whereas the cells negative for Gata1s 
differentiate and arrest their expansion. Next, we introduced empty vector, JAK1 wt or JAK1 
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F636del into the Gata1s expressing cells in order to study their joined effect on the fetal liver 
HSPCs proliferation (Fig. 25-26). 
 
Figure 25: Mimicking Gata1 mutated TMD without trisomy 21 in a murine fetal liver cell model 
to study the cooperation of Gata1s and JAK1 F636del. sgRNA (single guide RNA), APC 
(allophycocyanin), GFP (green fluorescent protein). 
 
 
Figure 26: Western blot analysis confirming the sole expression of Gata1s in the CRISPR/Cas9 
edited mouse fetal liver cells (mFLCs). GAPDH was used as loading control.  
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In the competitive growth assay setting were empty vector, JAK wt or JAK1 F636del 
were lentivirally introduced into the Gata1-edited HSPCs, JAK1 F636del had no additional 
impact on cell proliferation (Fig. 27) or maturation status (Fig. 28).  
Next, we conducted competitive growth assays, focusing on the JAK/STAT pathway. 
Similarly as in the previous experiment, empty vector, JAK wt or JAK1 F636del were lentivirally 
introduced into the Gata1-edited HSPCs. The cells were then cultured with various levels of 
interleukin 6 (IL6) in order to specifically stimulate JAK1 signaling. Overgrowth of the double-
positive (Gata1s + JAK1 F636del) cell population was not present in any of the used culturing 
conditions (Fig. 29). 
Additionally, cells were cultured in cytokine-depleted growth-restrictive conditions. 
Likewise, no difference between JAK1 wt and JAK1 F636del was visible in this experimental 
setting (Fig. 30). 
Moreover, JAK1 wt or JAK1 F636del were introduced into murine fetal HSPCs 
simultaneously with the GATA1 editing tools in order to monitor their combined effect on cell 
proliferation instantly after transduction. There was no proliferative advantage of the double 
positive HSPCs population (Gata1s + JAK1 F636del) (Fig. 31). 
 
 
Figure 27: Competitive growth experiment of the Gata1-edited murine fetal liver HSPCs (APC+) 
transduced at day 0 with empty vector (EV), JAK1 wt or JAK1 F636del (GFP+). The percentage 
of double positive cells (APC+GFP+) in the whole population of Gata1-edited cells (APC+) is 




Figure 28: Expression of the megakaryocytic marker CD41 after transduction (day 7 and 21) of 
the Gata1-edited cells with EV, JAK1 wt or JAK1 F636del. The double positive (APC+GFP+) cell 
population was used for the analysis.   
 
Figure 29: Competitive growth experiment of the Gata1-edited murine fetal liver HSPCs 
transduced at day 0 with empty vector (EV), JAK1 wt or JAK1 F636del. Cells were treated with 




Figure 30: Competitive growth experiment of the Gata1-edited murine fetal liver HSPCs 
transduced at day 0 with empty vector (EV), JAK1 wt or JAK1 F636del. Cells were cultured in 
the absence of mouse SFC. 
 
 
Figure 31: Simultaneous introduction of Gata1s together with JAK1 wt or JAK1 F636del into 
murine fetal liver HSPCs. The different cell fraction percentage from the total cell population 
after transduction is shown on the y axis. The x axis shows days after transduction (Day 0). 
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Project 2. Characterization of two novel fusion genes, AIF1L-ETV6 and ABL1-
AIF1L, resulting from a single chromosomal rearrangement in ETV6-ABL1-
positive pediatric ALL 
1. Novel fusion genes identified in a BCP-ALL harboring an ETV6-ABL1 fusion. 
We decided to characterize in detail the molecular background of an interesting BCP-
ALL harboring the ETV6-ABL1 fusion, diagnosed in our department in 2016. Both the clinical 
picture and immunophenotype (Table 4) did not differ from the previously described BCP-ALLs 
associated with an ETV6-ABL1 fusion gene.   
Cytogenetic analysis revealed a diploid male karyotype together with an isodicentric 
chromosome 7. No rearrangements of ETV6, RUNX1 and KMT2A gene loci were observed. 
Multiplex RT-PCR was positive for the ETV6-ABL1 fusion transcript and negative for BCR-ABL1, 
TCF3-PBX1, ETV6-RUNX1 and KMT2A-AFF1 fusion transcripts (Table 4). 
To assess the genomic profile of leukemic blasts, SNP array analysis, WES and RNAseq 
were applied. Four copy number aberrations were detected using SNP array. A 102 kb 
(kilobase) long monoallelic deletion on 3p affecting the FHIT gene, a 164 kb-long monoallelic 
deletion on 9p affecting the CDKN2A and CDKN2B genes and a loss of 1 copy of 7p, involving 
the IKZF1 gene, with gain of 1 copy of 7q corresponding to the presence of the isodicentric 
chromosome 7  (Lukes et al., 2018). 
Five non-synonymous substitutions affecting five genes were identified by WES, 
namely TPO A477T, SLC25A15 I254L, PCDHB15 R494Q, ELOVL4 A253S and OBP2A R118H. 
None of the affected genes have been, to the best of our knowledge, associated with ALL so 
far.  
We utilized RNAseq to identify leukemia-specific fusion transcripts. The presence of 
the type B (exon 5 to exon 2) ETV6-ABL1 fusion was confirmed and additionally, two novel in-
frame fusion transcripts were found. The ABL1-AIF1L fusion gene, were exon 1 from ABL1 is 
fused to exon 5 in AIF1L and the AIF1L-ETV6 fusion gene, were exon 4 in AIF1L is fused with 
exon 6 in ETV6 (Table 4, Fig. 33-34). 
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 Next, we analyzed the gene expression profile of the leukemic blasts. An in house 
cohort of 108 B-other BCP-ALL patients, negative for TCF3-PBX1, BCR-ABL1, ETV6-RUNX1 and 
KMT2A-involving fusions, was used for the gene expression analysis. Hierarchical clustering of 
the patients from this cohort using a gene set specific for BCR-ABL1-positive or BCR-ABL1-like-
positive ALL showed that the leukemic blasts harbored a BCR-ABL1-like gene expression 
signature (Fig. 32). 
 
2. Three fusion genes resulting from a single chromosomal rearrangement 
The AIF1L gene and the ABL1 gene have the same genomic orientation. Moreover, 
AIF1L is located on 9q downstream of ABL1. We therefore concluded that all three in-frame 
gene fusions resulted from a single chromosomal rearrangement (Fig. 33) (Lukes et al., 2018). 
We applied DNA-based long-distance PCR and described the exact intronic junction sequences 
of AIF1L-ETV6, ABL1-AIF1L and ETV6-ABL1, confirming the predicted chromosomal 
rearrangement on genomic level (Fig. 33-34). The insertion of a portion of 9p that included 
parts of the AIF1L and the ABL1 genes into chromosome 12 was balanced. There were no gains 
or losses at breakpoint sites in intron 5 of the ETV6 and intron 1 of the ABL1 gene. The 
breakpoint in intron 4 of the AIF1L gene harbored a deletion of 2 base pairs (Fig. 34).  
ABL1 gene insertion into the ETV6 gene represents the most frequent mechanism that 
results in the ETV6-ABL1 fusion in BCP-ALL as has been previously reported by our group 
(Zaliova et al., 2016; Zuna et al., 2010). In order to clarify, if the breakpoint of the telomeric 
9q segment in the AIF1L gene, which results in the ABL1-AIF1L and/or AIF1L-ETV6 fusions, 
occurs recurrently, we screened a cohort of 10 patients with ETV6-ABL1-positive leukemias 
from our previous study for the corresponding fusion transcripts. This cohort of patients 
included 5 cases with an unknown localization of the ETV6-ABL1 fusion and 5 patients with a 
confirmed insertion of the ABL1 gene into the ETV6 gene by cytogenetic analysis. No fusion 






3. The observed chromosomal rearrangement originated prenatally. 
The prenatal origin of the ETV6-ABL1 fusion has been previously demonstrated by us 
in a pediatric ALL case positive for the ETV6-ABL1 fusion gene (Zuna et al., 2010). We optimized 
a sensitive and specific PCR system in order to detect the patient‘s ETV6-ABL1 genomic fusion. 
We used the patient‘s Guthrie card (neonatal blood spot) for the analysis (Fig. 35). A positive 
result in the form of a PCR product of an expected length was obtained in 1 out of 7 reactions 
that contained a portion of the patient‘s Guthrie card (Fig. 36). The presence of the ETV6-ABL1 
fusion gene in the positive PCR product was verified by Sanger sequencing. Our results confirm 
the prenatal origin of the observed genomic rearrangement, which therefore probably 
represents the first leukemogenic event, followed by the acquisition of secondary aberrations 
in later stages of the leukemogenic process. Deletions in the IKZF1 and/or CDKN2A/B most 
likely represent the secondary hits (Fig. 35-37). 
 
4. Chimeric protein analysis reveals in vitro expression of AIF1L-ETV6. 
The two fusion genes AIF1L-ETV6 and ABL1-AIF1L have not been previously reported. 
Importantly, no disruptions of the AIF1L gene have been, to the best of our knowledge, 
described in leukemias so far. Therefore we decided to study these novel fusion genes in more 
detail. The allograft inflammatory factor 1 like (AIF1L) gene encodes three protein isoforms 
(Coordinators, 2017). The isoform 1 (NP_113614) consists of 150 amino acids with a predicted 
molecular weight of 17 kilodalton (kDa). It contains two centrally located EF-hand calcium-
binding domains (EF1, EF2). Its main function is binding and cross-linking actin (Fig. 38).  
The predicted molecular weight of the hypothetical chimeric protein encoded by the 
ABL1-AIF1L fusion gene is 14 kDa. The ABL1 moiety encodes 45 N-terminal amino acids of this 
chimeric protein that do not form any known functional domains. The AIF1L moiety encodes 
83 amino acids of ABL1-AIF1L that include the incomplete EF1 and the complete EF2 domains 
(Fig. 38). 
The predicted molecular weight of the hypothetical chimeric protein encoded by the 
AIF1L-ETV6 fusion gene is 22 kDa.  The AIF1L moiety encodes 67 N-terminal amino acids that 
include a part of the EF1 domain. The ETV6 moiety encodes 115 C-terminal amino acids that 
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include the ETS domain which mediates DNA binding of the wild type ETV6 (Fig. 38) (Lukes et 
al., 2018). 
We were not able to analyze the presence of the chimeric proteins ABL1-AIF1L and 
AIF1L-ETV6 in the patient’s primary leukemic cells due to insufficient quality and amount of 
protein isolated from the patient’s diagnostic bone marrow sample. Therefore we decided to 
study the expression of AIF1L-ETV6 and ABL1-AIF1L hypothetical chimeric proteins in HEK293T 
cells. The patient’s diagnostic bone marrow sample was used for cDNA amplification of the 
full-length coding regions of both of the fusion transcripts (Lukes et al., 2018). HEK293T cDNA 
was used for AIF1L wild type amplification. PCR products were analyzed by Sanger sequencing 
and showed that AIF1L wild type transcript represents the variant 1 of AIF1L, encoding for 
isoform 1. Moreover it revealed that the AIF1L-ETV6 transcript that is expressed by the 
leukemic cells lacks exon 3 of AIF1L. The third exon of AIF1L is also spliced out in the AIF1L 
wild type transcript variant 1 (Lukes et al., 2018).  
Coding sequences of the AIF1L-ETV6 and ABL1-AIF1L fusion transcripts were 
transfected into HEK293T cells. The presence of AIF1L wild type, AIF1L-ETV6 and ABL1-AIF1L 
proteins was analyzed with two antibodies targeting AIF1L. The AIF1L-N antibody was used for 
AIF1L-ETV6 chimeric protein detection, hence it detects the near N-terminal region of AIF1L 
which is involved in AIF1L-ETV6. The AIF1L-C antibody was used for ABL1-AIF1L chimeric 
protein detection, as it detects the C-terminal part of AIF1L which is involved in ABL1-AIF1L. 
Both the AIF1L-N and the AIF1L-C antibody detected the AIF1L wild type protein (Fig. 
39). We confirmed the expression of the chimeric protein AIF1L-ETV6 in HEK293T cells 
transfected with this particular construct using the AIF1L N-terminal antibody. The AIF1L-ETV6 
chimeric protein was located in both the nucleus and the cytoplasm, similarly to AIF1L wild 
type. We did not detect the expected chimeric protein ABL1-AIF1L in transfected HEK293T 












Figure 32: Gene expression analysis. Hierarchical clustering of 108 pediatric B-others BCP-ALL 
patients using a gene set specific for BCR-ABL1-positive or BCR-ABL1-like-positive ALLs. The 






Figure 33: A single chromosomal rearrangement resulted in three fusion genes, two of them 
novel. A portion of 9p that included parts of the AIF1L and the ABL1 genes was inserted into 
chromosome 12 into the ETV6 gene. This insertion and subsequent fusion on chromosome 12 
resulted in the ETV6-ABL1 and the AIF1L-ETV6 fusion genes. The remaining parts of 







Figure 34: (A) Fusion gene junctional sequences at genomic DNA level (gDNA) and at RNA level 
(cDNA). The junctional regions of the fusion genes were amplified by PCR in the case of gDNA 
and by RT-PCR in the case of cDNA. The PCR products were sequenced by Sanger sequencing. 
Non-templated inserted nucleotides (NN). (B) Reference sequences of the fusion gene 
breakpoint regions. The genomic coordinates correspond to GRCh37/hg19 reference genome 






Figure 35: Graphic representation of backtracking studies from Guthrie cards. First, a PCR 
system able to detect the studied aberration is optimized. Portion of the neonatal blood spot 
is used for the reaction. Results are validated by gel electrophoresis and Sanger sequencing. 
Emphasis should be given on limiting the possibility of sample contamination. 
 
Figure 36: Backtracking analysis of the ETV6-ABL1 fusion gene on the patient‘s Guthrie card. 
Lanes 1-7 show PCR products where pieces of the patient‘s Guthrie card containing samples of 
his newborn blood were included into the reaction. Lanes 8-17 represent positive control 
reactions and lanes 18-22 negative control reactions. For positive control reactions, DNA from 
patient‘s diagnostic bone marrow sample was diluted into control (“healthy”) DNA to a final 
concentration of 0.005% or 0.001% and used as template (lanes 8–12 and 13–17, respectively) 
(Lukes et al., 2018). In negative control reactions DNA of a healthy donor was applied. Both 
the positive and the negative control reactions contained a portion of the Guthrie card from a 
healthy donor without any blood, therefore achieving same PCR conditions in all reactions. The 
ETV6-ABL1 fusion was confirmed in the patient‘s newborn blood by Sanger sequencing of PCR 






Figure 37: The single chromosomal rearrangement resulting in 3 fusion genes, ETV6-ABL1, 
AIF1L-ETV6 and ABL1-AIF1L, probably represents the first leukemogenic hit which occured 
already in utero. The second hit is most likely represented by deletions in the IKZF1 and/or 





Figure 38: Representation of wild type (top scheme) and chimeric proteins (bottom scheme). 
Known functional protein domains are shown. The protein length is depicted in number of 
amino acids (aa). Positions corresponding to genomic breakpoints or junctions are displayed 
by dashed lines. Reference: ETV6-NM_001987 (NP_001978), ABL1-NM_007313 (NP_009297), 
AIF1L-NM_031426 (NP_113614). PNT (pointed domain), ETS (ETS domain), SH3 (SH3 domain), 
SH2 (SH2 domain), Tyr Kc (Tyrosine protein kinase, catalytic domain), FABD (F-actin binding 






Figure 39: The expression of expected chimeric proteins in HEK293T cells. Cytoplasmic (C) and 
nuclear (N) protein fractions were analyzed. Plasmid vector with coding sequences of empty 
vector, AIF1L wild type (wt), AIF1L-ETV6 and ABL1-AIF1L were transiently transfected into 
HEK293T cells. Antibodies recognizing N-terminal (AIF1L-N) and C-terminal (AIF1L-C) epitopes 
of AIF1L were used. AIF1L wild type expression together with the AIF1L-ETV6 chimer protein 
expression was confirmed with the AIF1L-N antibody. The AIF1L-C antibody was successfull in 
detecting AIF1L wild type, however no band corresponding to the expected ABL1-AIF1L 
chimeric protein was observed. Not even after the application of long signal acquisition (see 





Childhood acute leukemias are genetically diverse entities. The one technological 
breakthrough that precipitated major improvements in molecular genetics in general, and in 
diagnostics and dissection of childhood leukemias in particular within the last decade were 
high-throughput sequencing technologies. They helped identify novel and recurrent 
molecular aberrations in both acute myeloid and lymphoblastic leukemias, as well as allow 
fast and highly accurate investigation of individual cases (Iacobucci and Mullighan, 2017; 
Moorman, 2016; Papaemmanuil et al., 2016; Yohe, 2015). A significant number of these 
aberrations seem to play a major role in disease classification, management and risk 
stratification. Moreover, subsequent functional studies characterizing these molecular events 
help us gain insight into their role in the transformation of a normal hematopoietic cell into a 
malignant one. Understanding the pathogenesis of these processes is crucial for developing 
novel targeted therapies.  
Focus of my thesis rests mainly in a thorough identification and characterization of 
genetic events in TMD and BCP-ALL. It includes both a detailed dissection of novel genetic 
mutations and fusion genes, as well as presentation of numerous experimental in vitro 
approaches that focus on the functional description of these particular aberrations. The main 
aim was to decipher an alternative pathogenesis of TMD development in the absence of 
trisomy 21 and to characterize a chromosomal rearrangement in BCP-ALL resulting in the 
production of multiple fusion genes (Lukes et al., 2020; Lukes et al., 2018).  
Moreover, I have also participated on a project aiming to study the feasibility of the 
identification of PML-RARA, CBFB-MYH11 and RUNX1-RUNX1T1 genomic fusion sequences 
using targeted sequencing. The identified fusion gene breakpoint sequences subsequently 
served for the design of patient-specific qPCR systems for MRD monitoring. We showed that 
fusion gene-based MRD monitoring represents a superior tool for therapy response evaluation 
than the widely used fusion-transcript based approach. By applying the fusion gene-based 
approach a higher sensitivity was reached. Importantly, we show that fusion gene breakpoint 
identification is feasible and enables unambiguously interpretable monitoring of MRD in AML 
patients harboring the PML-RARA, CBFB-MYH11 and RUNX1-RUNX1T1 fusions (Lukes et al., 
manuscript under consideration). 
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Last but not least, I participated in studying the frequency of H1038/Q1072 ZEB2 
mutations in pediatric B-other ALL and the impact of these aberrations on patient outcome 
(Zaliova et al., manuscript in revision). 
TMD is a leukemia-like disease that originates from fetal hematopoietic cells. In the 
past two decades substantial effort has been invested into our understanding of the 
pathogenesis of TMD. Trisomy 21 seems to be a necessary requirement for the development 
of this preleukemic condition (Banno et al., 2016; Carpenter et al., 2005; Kruger, 2007). 
However, the exact mechanism of its contribution still remains elusive. A minimal amplified 
region together with particular genes, namely RUNX1, ETS2, ERG and miR-125b-2, on 
chromosome 21 have been proposed to be responsible for the expansion of early 
hematopoietic progenitors, represented mainly by megakaryocytic progenitors (Banno et al., 
2016; Chou et al., 2008; Klusmann et al., 2010). Most patients suffering from TMD have 
constitutional trisomy 21, in the form of Down syndrome or mosaic Down syndrome (Malinge 
et al., 2009; Roberts and Izraeli, 2014). Rarely TMD also occurs in non-DS patients. However, 
all described cases of this nature harbored somatic trisomy 21 (Carpenter et al., 2005; 
Magalhaes et al., 2005; Yumura-Yagi et al., 1992).  
We identified, to the best of our knowledge, the first case of TMD with no involvement 
of chromosome 21. To rule out mosaicism for trisomy 21 or a partial trisomy 21, two 
independent cytogenetic analyses were performed, both of which revealed a normal 
karyotype without any numerical aberrations of the chromosome in question. Furthermore, 
the SNP array analysis of the blast population reliably excluded the presence of trisomy 21. 
The sequential acquisition of uniform genetic events has established TMD in the past as a 
perfect model of myeloid leukemogenesis (Garnett et al., 2020; Hitzler and Zipursky, 2005). 
Our observations, discussed below, point to additional mechanisms that may participate in 
TMD pathogenesis. More importantly, the absence of trisomy 21 in the blast population 
questions the (absolute) necessity of the additional chromosome 21 in TMD origin. 
To further characterize the genetic background of this exceptional TMD, we performed 
next generation sequencing and identified novel somatic mutations in the GATA1, JAK1, 
SPIRE2 and FN1 genes. Normal definitive hematopoiesis is not only maintained by two copies 
of the 21 chromosome, but also by full-length GATA1 (Crispino, 2005). Mutations in the GATA1 
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gene are the second essential factor that was postulated as necessary for TMD development 
(Banno et al., 2016; Carpenter et al., 2005; Gialesaki et al., 2018; Xu et al., 2003). These 
aberrations are usually located in the second exon and lead to the exclusive production of an 
N-terminally truncated variant called GATA1s (Shimizu et al., 2008). The dysregulation of 
GATA1, perturbs a complex transcriptional network regulating HSCs development, that 
eventually causes an accumulation of immature progenitors (Banno et al., 2016; Shimizu et 
al., 2008; Shimizu et al., 2009) in a stage specific manner (Gialesaki et al., 2018). When GATA1s 
expression was induced in human fetal, neonatal and adult HSPCs, terminal differentiation 
and progenitor cell accumulation was present only in the fetal ontogeny (Gialesaki et al., 
2018). The distinct effects of GATA1s in individual developmental stages of hematopoiesis 
could explain the temporary nature of TMD, which is a self-limiting disease usually resolving 
spontaneously within the first few months after birth (Klusmann et al., 2008). The 
spontaneous remission coincides with the gradual transition of hematopoiesis from fetal liver 
into the bone marrow (Dzierzak and Speck, 2008; Hitzler and Zipursky, 2005). When hepatic 
hematopoiesis ceases, it may result in loss of necessary microenvironment crucial for TMD 
blast growth. Possibly, unknown factors in the bone marrow microenvironment may stop the 
blast proliferation (Miyauchi and Kawaguchi, 2014). The novel GATA1 mutation, GATA1 
D65_C228del, described by us, differs significantly from the common mutations resulting in 
the production of GATA1s, usually represented by small duplications, insertions and deletions 
(Rainis et al., 2003). GATA1 D65_C228del results in a large deletion spanning between multiple 
exons. We proved the production of the GATA1 chimeric protein in a cell model and tracked 
its localization into the nucleus, similarly to GATA1 wt and GATA1s. Interestingly the GATA1 
D65_C228del protein lacks the whole NZF and a part of TAD. Conversely, GATA1s lacks only 
TAD. Point mutations in the NFZ are commonly present in benign congenital anemias (Freson 
et al., 2001; Freson et al., 2002; Mehaffey et al., 2001; Nichols et al., 2000). However, we have 
not found any published information about cases of TMD or other hematological malignancies 
harboring aberrations in the GATA1 gene leading to complete NZF loss. The two major 
functions of NZF are to enable and subsequently stabilize GATA binding to DNA and to mediate 
the interaction between GATA1 and its essential cofactor FOG1 (Lowry and Mackay, 2006; 
Trainor et al., 2000; Trainor et al., 1996; Tsang et al., 1997). Interestingly, abrogation of the 
interaction between GATA1 and FOG1 results in loss of differentiation, however proliferation 
of immature megakaryocytes is conserved (Kuhl et al., 2005). The association of GATA1 with 
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FOG1 is crucial during embryonic hematopoiesis (Shimizu et al., 2004). Mutations perturbing 
this interaction lead to essential thrombocytopenia (Chang et al., 2002; Nichols et al., 2000). 
Moreover, the indispensability of NZF was demonstrated previously in two pivotal rescue 
studies. In transgenic mice, NZF was required for definite erythropoiesis (Shimizu et al., 2001), 
and in GATA1-null erythroid cells, NZF rescued erythroid differentiation (Weiss et al., 1997). It 
has been postulated that NZF loss may affect the function of GATA1 more severely than TAD 
loss (Shimizu et al., 2001). When expressed at high levels, GATA1s was able to rescue definite 
erythropoiesis, however the NZF lacking GATA1 variant had no rescue effect, regardless of 
expression levels (Shimizu et al., 2001). We therefore hypothesize, that the novel GATA1 
mutation identified in our patient, resulting in complete loss of NZF together with partial loss 
of TAD, negatively influences GATA1 function in a more severe way when compared with 
GATA1 aberrations found in trisomy 21-associated TMDs. The aberrant GATA1 D65_C228del 
isoform is predicted to lose transactivation potential, together with partially losing the ability 
to recognize DNA binding sites. Conversely, the GATA1s isoform loses only transactivation 
potential, therefore possibly compromising fetal hematopoiesis to a lesser extent than GATA1 
D65_C228del. Nevertheless, the effect of GATA1 D65_C228del remains limited to fetal 
hematopoiesis, parallel to GATA1s. Interestingly, GATA1s alone, similarly to trisomy 21 alone, 
is insufficient to cause TMD. This has been exemplified by the presence of a germline GATA1 
mutation, resulting in GATA1s production, in a family without TMD occurrence (Hollanda et 
al., 2006).  In comparison, the GATA1 D65_C228del isoform may possibly be able to induce 
the non-DS-TMD alone. 
Tumorigenesis however only rarely results from a single genetic hit and usually 
requires multiple cooperating aberrations (Inaba et al., 2013). The novel JAK1 deletion, JAK1 
F636del, identified by us represented the most probable candidate involved in TMD induction, 
together with the aberrant GATA1. Mutated JAK genes are recurrently found in various 
hematological malignancies, importantly also in AML and AMKL (Chen et al., 2012; Jeong et 
al., 2008; Nikolaev et al., 2013; Xiang et al., 2008; Zhang et al., 2012). JAK1 F636del results in 
the loss of one highly conserved phenylalanine on position 636 located in the pseudokinase 
domain a region frequently harboring activating mutations (Flex et al., 2008; Haan et al., 
2010). F636 belongs to a triad of aminoacids which, together with V658 and F575, likely 
controls the catalytic activity of JAK1 (Toms et al., 2013). Hence, we expected that its loss will 
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significantly impact the structure and possibly function of JAK1. However, homology modeling 
suggested the compatibility of F636 loss with both the active and inactive conformations of 
JAK1, together with a third possible “alternative” conformation, resembling the inactive state. 
We showed that catalytic activity of JAK1 F636del is preserved, however phosphorylation 
levels of JAK1 and STATs, its downstream signaling molecules, were lower when compared to 
their wild type counterparts, implicating that F636del results in decreased kinase activity. 
Typical JAK pseudokinase activating mutations, including JAK2 V617F, which is present in the 
majority of polycythemia vera patients, cause activation of the kinase domain (James et al., 
2005). Similarly, the JAK1 V658F variant which is homologous to JAK2 V617F, activates the 
JAK1/STAT3 pathway (Hornakova et al., 2009; Jeong et al., 2008; Mullighan et al., 2009c). 
Furthermore, the activating potential of various aberrations affecting JAK1 via the Ba/F3 cell 
assay has been demonstrated (Arulogun et al., 2017; Li et al., 2017). In the case of JAK1 
F636del, IL3 independent growth was not achieved, therefore questioning the oncogenic 
potential of this particular deletion. We hypothesized that JAK1 F636del may only exert its 
effect in the context of mutated GATA1, due to the delicate interplay between these two 
aberrations in a site and cell specific manner. Therefore, we assessed the cooperation of JAK1 
F636del with GATA1s by utilizing a mouse fetal liver HSPC model, successfully mimicking the 
trisomy 21-independent TMD. However, even in this setting no impact on cell maturation and 
proliferation was registered. The involvement, if any, of JAK1 F636del in the pathogenesis of 
the trisomy 21-independent TMD remains elusive. Our findings regarding JAK1 complement 
the recently published data from the largest sequencing study of TMD and myeloid leukemia 
of Down syndrome (ML-DS) patients conducted so far. Labuhn and colleagues showed that 
tyrosine kinase mutations, most prevalently JAK mutations, are very common in both patients 
with TMD and in patients who progress to ML-DS (Labuhn et al., 2019). Interestingly, the vast 
majority of JAK aberrations found in ML-DS patients were either already documented as gain-
of-function mutations (Baxter et al., 2005; Bercovich et al., 2008; Kiyoi et al., 2007; Malinge et 
al., 2008), or were proved activating in various cell assays by Labuhn and colleagues (Labuhn 
et al., 2019). On the other hand, none of the JAK mutations found in this large cohort of TMD 
patients was shown to be activating (Labuhn et al., 2019). Moreover, another study identified 
JAK3 loss-of-function mutations in DS-TMD and AMKL (De Vita et al., 2007). Some of these 
mutations were also previously found in patients with severe combined immunodeficiency 
(De Vita et al., 2007; O'Shea et al., 2004). Due to their abundance in TMD, it seems that JAK 
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gene mutations, are not merely passenger mutations and may therefore play a role in the 
pathogenesis of this preleukemia, however the mechanism of their contribution may 
significantly differ from that of previously described gain-of-function mutations.  
Alternatively, the novel mutations in SPIRE2 (SPIRE2 R471W) and FN1 (FN1 R2420C) 
genes, identified by WES, may also contribute to the development of this unique TMD. SPIRE2, 
which encodes Spire type actin nucleation factor 2, plays a role in asymmetric oocyte division. 
It mediates asymmetric spindle positioning by assembling the actin network and drives polar 
body extrusion by promoting assembly of the cleavage furrow (Pfender et al., 2011). The FN1 
gene encodes fibronectin 1, a glycoprotein involved in cell migration and adhesion processes 
like wound healing, metastasis and blood coagulation (Barbazan et al., 2017; Grinnell, 1984; 
Li et al., 2019; Wang and Ni, 2016). However, current knowledge about the involvement of 
SPIRE2 and FN1 in hematological malignancies is very limited and we can therefore only 
speculate about their involvement in trisomy 21-independent TMD pathogenesis. 
Chromosomal rearrangements resulting in fusion gene production represent a 
hallmark of pediatric ALL (Iacobucci and Mullighan, 2017; Mitelman et al., 2007). The ETV6-
ABL1 fusion gene is a rare, but recurrent, genetic event in both children and adults diagnosed 
with ALL (Zaliova et al., 2016). Our laboratory focused its research on the characterization of 
patients harboring the ETV6-ABL1 fusion and published a number of pivotal articles regarding 
this topic in the past (Zaliova et al., 2016; Zuna et al., 2010). In the presented study we 
characterize a unique childhood BCP-ALL positive for the ETV6-ABL1 fusion gene. ETV6-ABL1 
originates either from the insertion of a part of the ABL1 gene into the ETV6 gene, which is 
located on chromosome 12, or from the insertion of a part of ETV6 into ABL1 located on 
chromosome 9 (Zaliova et al., 2016). Rarely, additional chromosomes are involved in the 
rearrangement (La Starza et al., 2002; Tirado et al., 2005). The fusion identified by us was 
localized on chromosome 12, supporting the fact that ABL1 insertion into ETV6 represents a 
more common mechanism over the opposite event (Zaliova et al., 2016). The insertion was 
cryptic, similarly to the majority of previously described cases. Therefore, no abnormalities 
were detected during routine FISH analysis with the ETV6 probe.  
In leukemias, commonly one or two in-frame fusion genes originate from a single 
chromosomal rearrangement. We identified three in-frame fusion genes, namely ETV6-ABL1, 
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ABL1-AIF1L and AIF1L-ETV6. By detecting the exact intronic junction sequences of all three in-
frame fusions we confirmed that they originated from a single rearrangement, which 
represents a rare event. Reciprocal in-frame fusion transcripts can be detected in recurrent 
fusions like BCR-ABL1, KM2TA-AFF1, ETV6-RUNX1, PML-RARA, CBFB-MYH11 and RUNX1-
RUNX1T1 represented by ABL1-BCR, AFF1-KMT2A, RUNX1-ETV6, RARA-PML, MYH11-CBFB 
and RUNX1T1-RUNX1, respectively (Kowarz et al., 2007; Loncarevic et al., 2002; Romana et al., 
1995a, Lukes et al., manuscript under consideration). Despite the fact that these additional 
fusion genes are undetectable in a proportion of patients, certain studies suggest that they 
might contribute to leukemia phenotype or perhaps have even oncogenic potential, and 
therefore are not mere passenger aberrations (Bursen et al., 2010; Gaussmann et al., 2007; 
Rafiei et al., 2015; Zheng et al., 2009). This has been nicely demonstrated on a number of 
reciprocal KMT2A fusion proteins (Marschalek, 2020). For example, in mice the AFF1-KMT2A 
fusion protein, reciprocal to KMT2A-AFF1, was capable of inducing ALL, even without the 
direct KMT2A-AFF1 fusion protein (Bursen et al., 2010). Moreover, the oncogenic potential of 
the NEBL-KMT2A fusion protein, reciprocal to KMT2A-NEBL, has been shown in transfected 
cells (Emerenciano et al., 2013). The BCR-ABL1 fusion gene is a molecular hallmark of CML 
(Zhou et al., 2018). Its reciprocal counterpart, the ABL1-BCR fusion gene, has been proposed 
to exhibit leukemogenic potential (Zheng et al., 2009). The ABL1-BCR chimeric protein 
increased short term stem cell capacity of murine hematopoietic stem cells and the 
proliferation of early progenitors. Interestingly, BCR-ABL1 exclusively assigned the cells a 
myeloid phenotype, whereas ABL1-BCR forced the B-cell commitment. By influencing the 
lineage commitment, ABL1-BCR could possibly contribute to leukemia phenotype 
determination (Zheng et al., 2009). However, the exact role of ABL1-BCR in CML still remains 
to be defined.  
Moreover, we demonstrated that the fusion genes likely represent the first 
leukemogenic event in this BCP-ALL case by revealing the prenatal origin of the fusions by 
backtracking ETV6-ABL1 into archived neonatal blood withdrawn from the patient right after 
birth. These data support our previous findings suggesting that prenatal origin of ETV6-ABL1 
is not uncommon in childhood ALL (Zuna et al., 2010). Leukemia manifestation occurred 
almost 3 years after birth in the studied patient. From this we can assume that the combined 
effect of the ETV6-ABL1, ABL1-AIF1L and AIF1L-ETV6 is insufficient to launch overt leukemia, 
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similarly to ETV6-ABL1 alone. Additional aberrations that cooperate with ETV6-ABL1 are 
necessary for leukemia development. In 80% of ALL cases positive for the ETV6-ABL1 fusion 
these lesions are represented by deletions in the CDKN2A/B and IKZF1 genes, as has been 
demonstrated previously by us (Zaliova et al., 2016; Zuna et al., 2010). Importantly, CDKN2A/B 
and IKZF1 deletions are also recurrently found in BCR-ABL1-positive ALLs. Aside from 
similarities in their genomic profiles, these two entities share an analogous gene expression 
profile (Mullighan et al., 2007; Roberts et al., 2014b; Zaliova et al., 2016). In the presented 
BCP-ALL both deletions in CDKN2A/B and IKZF1 were identified, likely representing the second 
hit aberrations contributing to the process of leukemogenesis. Moreover, these findings 
support the notion, that CDKN2A/B and IKZF1 silencing is a common feature of ETV6-ABL1-
positive leukemia.  
The ETV6 protein plays an important role in hematopoiesis, especially in the bone 
marrow, and during embryonic development (De Braekeleer et al., 2012; Wang et al., 1997; 
Wang et al., 1998). The main functions of the ABL1 gene concern cell adhesion and motility, 
autophagy, receptor endocytosis and actin binding (Colicelli, 2010; De Braekeleer et al., 2011).  
The ETV6-ABL1 fusion gene can be found not only in ALL, as described here, but also in AML 
and myeloproliferative neoplasms (Zaliova et al., 2016). It effects cell survival, proliferation 
and transforming capacity similarly as BCR-ABL1 (Hannemann et al., 1998; Okuda et al., 1996). 
Their effect varies in mice, were BCR-ABL1 induces leukemia and ETV6-ABL1 a chronic 
myeloproliferation (Million et al., 2002). In comparison with the ETV6 and ABL1 genes, 
information about the biological role and function of AIF1L, except its involvement in actin 
bundling, remains unclear (Lu et al., 2017; Schulze et al., 2008). Physiologically, AIF1L is 
expressed in a variety of tissues including the hematopoietic system.  Importantly, it is also 
expressed in the majority of ALLs, according to our RNA sequencing data. However, its 
expression levels vary significantly. The here described AIF1L-ETV6 and ABL1-AIF1L fusion 
genes represent, to the best of our knowledge, the first leukemia associated disruptions of 
the AIF1L gene. Insufficient amount of available material prevented us from the direct analysis 
of chimeric AIF1L protein expression in the leukemic blast population. Therefore we utilized 
an in vitro approach and successfully localized the AIF1L-ETV6 fusion protein in the nucleus of 
transfected HEK293T cells. The ETV6 DNA-binding domain is preserved in this chimeric 
protein, therefore possibly enabling the recognition of ETV6 binding motifs and subsequent 
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DNA binding. It may play a similar role as in the MN1-ETV6 fusion protein, which can be found 
in patients with myelodysplastic syndrome and AML (Buijs et al., 1995), where the ETV6 DNA-
binding domain is also preserved, and is together with the MN1 moiety capable of 
transforming murine fibroblasts (Buijs et al., 2000). In this case MN1 probably functions as a 
transcriptional co-activator, instead of serving as a transcription factor capable of binding to 
a specific DNA sequence (van Wely et al., 2003). Moreover, in translocations involving the BTL 
and PAX5 genes, the ETV6 DNA-binding domain is also part of the fusion protein, suggesting 
possible similarities in the mechanisms involved (Bohlander, 2005; Cazzaniga et al., 2001; 
Cools et al., 1999; Fazio et al., 2008). However, additional functional studies would be required 
to examine this hypothesis and reveal the exact function of AIF1L-ETV6. We did not detect the 
ABL1-AIF1L chimeric protein, despite the fact that the antibody showed a robust signal for 
AIF1L wild type protein. These data imply that ABL1-AIF1L is unstable or is not expressed at 
all.  
In conclusion, I have participated in the description and detailed characterization of 
the molecular background behind two unique hematological entities: a TMD that evolved in a 
trisomy 21-independent setting and a ETV6-ABL1-positive BCP-ALL resulting from a single 
chromosomal translocation of prenatal origin. Deciphering the role of these molecular events 
helps us better understand the process of leukemogenesis in both childhood AML and ALL. 
During my medical and doctoral studies I had the honor of personally meeting both 
Prof. Koutecký and Prof. Hrodek, the two pioneers, who introduced pediatric hematology and 
oncology in late 1960s into general medical practice in the Czech Republic, formerly 
Czechoslovakia.  The initial protocols that they implemented gave a mere 30% disease-free 
survival of ALL (Kavan et al., 1997; Koutecky, 1990). Advances in diagnosis, disease monitoring 
and treatment have risen this bar as high as to 90% in the 21st century (Stary et al., 2014). I 
am glad that during my Ph.D. studies I was able to be part of a team of leading scientist and 






The identification and characterization of genetic aberrations in childhood leukemias 
plays a pivotal role in understanding the process of leukemogenesis which subsequently helps 
us in developing novel therapeutic strategies and tailoring patient-specific treatments. In this 
study we identified novel mutations in protein coding genes together with a chromosomal 
aberration resulting in the production of previously undescribed fusion genes, providing 
significant information on the genetic background of two childhood acute leukemia entities, 
the transient myeloproliferative disorder and the ETV6-ABL1-positive B-cell precursor acute 
lymphoblastic leukemia. 
We described the first case of trisomy 21-independent GATA1 mutation-positive TMD. 
Our findings contradict the generally accepted claim that this preleukemic condition, which 
presents an ideal model to study the individual steps of leukemogenesis, requires the extra 
chromosome 21 during its development. We identified novel molecular aberrations in the 
JAK1 and GATA1 genes which we functionally characterized. JAK/STAT signaling studies 
together with various cell based models question the contribution of JAK1 F636del in the 
pathogenesis of TMD. We hypothesize, that the large in-frame GATA1 deletion which results 
in the production of an aberrant protein lacking the N-terminal zinc finger, impacts fetal 
hematopoiesis more severely when compared to GATA1s and may therefore trigger the 
trisomy 21-independent TMD condition alone.   
Moreover, we described two novel fusion genes, AIF1L-ETV6 and ABL1-AIF1L, which 
result from a single chromosomal rearrangement in an ETV6-ABL1-positive BCP-ALL. We 
demonstrated the prenatal origin of this unique rearrangement and hence its inability to cause 
overt leukemia. 
Last but not least, we showed that fusion gene-based MRD monitoring is superior to 
fusion transcript-based MRD monitoring in pediatric AML patients positive for the PML-RARA, 
CBFB-MYH11 and RUNX1-RUNX1T1 fusion genes. Importantly we demonstrate that fusion 
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KMT2A   Lysine Methyltransferase 2A 
KRAS    KRAS Proto-Oncogene 
LMO    LIM Domain Only 
LMO1    LIM Domain Only 1 
LMO2    LIM Domain Only 2 
LSI    locus specific identifier 
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miR-125b-2   microRNA 125b-2 
ML-DS    myeloid leukemia of Down syndrome 
MLL    mixed lineage leukemia 
MLLT1 (ENL)   MLLT1 Super Elongation Complex Subunit 
MLLT3 (AF9)   MLLT3 Super Elongation Complex Subunit 
MNX1    Motor Neuron And Pancreas Homeobox 1 
MRD    minimal residual disease 
MYB    MYB Proto-Oncogene 
MYC    MYC Proto-Oncogene 
MYH11   Myosin Heavy Chain 11 
N    nuclear 
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TAL1     T-Cell Acute Lymphocytic Leukemia 1 
TAL2     T-Cell Acute Lymphocytic Leukemia 2  
TBP    TATA-Box Binding Protein 
TCF3    Transcription Factor 3 
Ter119    Ter119 antigen 
TF1    human erythroleukemia cell line 
TKI    tyrosine kinase inhibitor 
TLX1     T Cell Leukemia Homeobox 1 
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